OA16437A - Compounds and their use. - Google Patents
Compounds and their use. Download PDFInfo
- Publication number
- OA16437A OA16437A OA1201300221 OA16437A OA 16437 A OA16437 A OA 16437A OA 1201300221 OA1201300221 OA 1201300221 OA 16437 A OA16437 A OA 16437A
- Authority
- OA
- OAPI
- Prior art keywords
- compound
- methyl
- ium
- trioxo
- azabicyclo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 135
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 54
- 108020004256 beta-Lactamases Proteins 0.000 claims abstract description 50
- 102000006635 beta-Lactamases Human genes 0.000 claims abstract description 50
- 230000003115 biocidal Effects 0.000 claims abstract description 43
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 34
- 108010068385 carbapenemase Proteins 0.000 claims abstract description 31
- 201000009910 diseases by infectious agent Diseases 0.000 claims abstract description 28
- 239000011780 sodium chloride Substances 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 230000000694 effects Effects 0.000 claims abstract description 18
- 239000003112 inhibitor Substances 0.000 claims abstract description 17
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims abstract description 16
- 239000002132 β-lactam antibiotic Substances 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 230000003389 potentiating Effects 0.000 claims abstract description 12
- -1 carboxylate anion Chemical group 0.000 claims description 80
- 239000000203 mixture Substances 0.000 claims description 67
- 229960002182 IMIPENEM Drugs 0.000 claims description 47
- 239000002253 acid Substances 0.000 claims description 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 30
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims description 27
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims description 27
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims description 27
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims description 27
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims description 27
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims description 27
- 229940079866 intestinal antibiotics Drugs 0.000 claims description 27
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims description 27
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 241000894006 Bacteria Species 0.000 claims description 24
- ORFOPKXBNMVMKC-DWVKKRMSSA-O (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-3-(pyridin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 ORFOPKXBNMVMKC-DWVKKRMSSA-O 0.000 claims description 23
- 229960000484 Ceftazidime Drugs 0.000 claims description 23
- 150000001780 cephalosporins Chemical class 0.000 claims description 22
- AVAACINZEOAHHE-VFZPANTDSA-N Doripenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](CNS(N)(=O)=O)C1 AVAACINZEOAHHE-VFZPANTDSA-N 0.000 claims description 21
- 229960000895 doripenem Drugs 0.000 claims description 21
- IVBHGBMCVLDMKU-GXNBUGAJSA-N Piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 claims description 19
- 229960002292 piperacillin Drugs 0.000 claims description 19
- 125000000623 heterocyclic group Chemical group 0.000 claims description 17
- 239000000651 prodrug Substances 0.000 claims description 17
- 229940002612 prodrugs Drugs 0.000 claims description 17
- 230000000875 corresponding Effects 0.000 claims description 16
- 150000002148 esters Chemical class 0.000 claims description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 16
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 15
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 14
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 150000002367 halogens Chemical class 0.000 claims description 13
- DMJNNHOOLUXYBV-PQTSNVLCSA-N Meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 claims description 12
- 229960002260 meropenem Drugs 0.000 claims description 12
- 229940041011 Carbapenems Drugs 0.000 claims description 10
- NKBWMBRPILTCRD-UHFFFAOYSA-M 2-methylheptanoate Chemical compound CCCCCC(C)C([O-])=O NKBWMBRPILTCRD-UHFFFAOYSA-M 0.000 claims description 9
- 229950005258 CEFALONIUM Drugs 0.000 claims description 9
- NBFNMSULHIODTC-CYJZLJNKSA-N Cefadroxil Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 claims description 9
- 229960004841 Cefadroxil Drugs 0.000 claims description 9
- FMZXNVLFJHCSAF-DNVCBOLYSA-N Cefalonium Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)CC=3SC=CC=3)[C@H]2SC1 FMZXNVLFJHCSAF-DNVCBOLYSA-N 0.000 claims description 9
- 229940041009 Monobactams Drugs 0.000 claims description 9
- 150000002961 penems Chemical class 0.000 claims description 9
- 229960004261 Cefotaxime Drugs 0.000 claims description 8
- YWKJNRNSJKEFMK-PQFQYKRASA-N (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-(5,6,7,8-tetrahydroquinolin-1-ium-1-ylmethyl)-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 YWKJNRNSJKEFMK-PQFQYKRASA-N 0.000 claims description 7
- 229950003588 Axetil Drugs 0.000 claims description 7
- 229960003644 Aztreonam Drugs 0.000 claims description 7
- WZPBZJONDBGPKJ-VEHQQRBSSA-N Aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 claims description 7
- 206010060945 Bacterial infection Diseases 0.000 claims description 7
- HVFLCNVBZFFHBT-ZKDACBOMSA-N Cefepime Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1C[N+]1(C)CCCC1 HVFLCNVBZFFHBT-ZKDACBOMSA-N 0.000 claims description 7
- 229950009592 Cefquinome Drugs 0.000 claims description 7
- 241000588921 Enterobacteriaceae Species 0.000 claims description 7
- 229960002100 cefepime Drugs 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 150000004677 hydrates Chemical class 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- ZBHXIWJRIFEVQY-IHMPYVIRSA-N Ceftiofur Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC(=O)C1=CC=CO1 ZBHXIWJRIFEVQY-IHMPYVIRSA-N 0.000 claims description 6
- JWCSIUVGFCSJCK-CAVRMKNVSA-N Disodium Moxalactam Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CO[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C1=CC=C(O)C=C1 JWCSIUVGFCSJCK-CAVRMKNVSA-N 0.000 claims description 6
- JUZNIMUFDBIJCM-ANEDZVCMSA-N Invanz Chemical compound O=C([C@H]1NC[C@H](C1)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)NC1=CC=CC(C(O)=O)=C1 JUZNIMUFDBIJCM-ANEDZVCMSA-N 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 229960005229 ceftiofur Drugs 0.000 claims description 6
- 229960002770 ertapenem Drugs 0.000 claims description 6
- 150000002960 penicillins Chemical class 0.000 claims description 6
- LXLDMYXULSBRCX-HZEONMFJSA-N (6R,7R)-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-ylidene)-2-nitrosoacetyl]amino]-8-oxo-3-[(E)-[2-oxo-1-[(3R)-pyrrolidin-3-yl]pyrrolidin-3-ylidene]methyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N1SC(N)=N\C1=C(\N=O)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(\C=C/3C(N([C@H]4CNCC4)CC\3)=O)CS[C@@H]21 LXLDMYXULSBRCX-HZEONMFJSA-N 0.000 claims description 5
- 229950004259 Ceftobiprole Drugs 0.000 claims description 5
- HGGAKXAHAYOLDJ-FHZUQPTBSA-N Faropenem Chemical compound S([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1[C@H]1CCCO1 HGGAKXAHAYOLDJ-FHZUQPTBSA-N 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- JSVCEVCSANKFDY-SFYZADRCSA-N carbacephem Chemical compound C1CC(C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)C)[C@H]21 JSVCEVCSANKFDY-SFYZADRCSA-N 0.000 claims description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 5
- 229960000379 faropenem Drugs 0.000 claims description 5
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 5
- 125000004043 oxo group Chemical group O=* 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 125000004953 trihalomethyl group Chemical group 0.000 claims description 5
- 229950006523 CILEXETIL Drugs 0.000 claims description 4
- RDLPVSKMFDYCOR-UEKVPHQBSA-N Cefradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 claims description 4
- 229960002588 Cefradine Drugs 0.000 claims description 4
- CZTQZXZIADLWOZ-CRAIPNDOSA-N Cephaloridine Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)[O-])=C2C[N+]1=CC=CC=C1 CZTQZXZIADLWOZ-CRAIPNDOSA-N 0.000 claims description 4
- HGBLNBBNRORJKI-WCABBAIRSA-N Ciclacillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C1(N)CCCCC1 HGBLNBBNRORJKI-WCABBAIRSA-N 0.000 claims description 4
- 229960004244 Cyclacillin Drugs 0.000 claims description 4
- 229960004273 Floxacillin Drugs 0.000 claims description 4
- UIOFUWFRIANQPC-JKIFEVAISA-N Floxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(F)C=CC=C1Cl UIOFUWFRIANQPC-JKIFEVAISA-N 0.000 claims description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 4
- BPLBGHOLXOTWMN-MBNYWOFBSA-N Phenoxymethylpenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)COC1=CC=CC=C1 BPLBGHOLXOTWMN-MBNYWOFBSA-N 0.000 claims description 4
- 229950009297 Pivoxil Drugs 0.000 claims description 4
- 229950000033 Proxetil Drugs 0.000 claims description 4
- 229960004659 Ticarcillin Drugs 0.000 claims description 4
- OHKOGUYZJXTSFX-KZFFXBSXSA-N Ticarcillin Chemical compound C=1([C@@H](C(O)=O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)C=CSC=1 OHKOGUYZJXTSFX-KZFFXBSXSA-N 0.000 claims description 4
- 241000209149 Zea Species 0.000 claims description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- UCKZMPLVLCKKMO-LHLIQPBNSA-N cephamycin Chemical class S1CC(C)=C(C(O)=O)N2C(=O)[C@@H](C)[C@]21OC UCKZMPLVLCKKMO-LHLIQPBNSA-N 0.000 claims description 4
- 235000005822 corn Nutrition 0.000 claims description 4
- 235000005824 corn Nutrition 0.000 claims description 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 4
- VTDCYOLLYVAJSY-UHFFFAOYSA-N cyclohexyl propan-2-yl carbonate Chemical compound CC(C)OC(=O)OC1CCCCC1 VTDCYOLLYVAJSY-UHFFFAOYSA-N 0.000 claims description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 4
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000005843 halogen group Chemical group 0.000 claims description 4
- 125000006502 nitrobenzyl group Chemical group 0.000 claims description 4
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 claims description 4
- 235000019371 penicillin G benzathine Nutrition 0.000 claims description 4
- VAMSVIZLXJOLHZ-QWFSEIHXSA-N 2-[(Z)-[1-(2-amino-1,3-thiazol-4-yl)-2-[[(3S)-2,2-dimethyl-4-oxo-1-sulfooxyazetidin-3-yl]amino]-2-oxoethylidene]amino]oxyacetic acid Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1 VAMSVIZLXJOLHZ-QWFSEIHXSA-N 0.000 claims description 3
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims description 3
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-oxazolidone Chemical class O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 3
- 108010062877 Bacteriocins Proteins 0.000 claims description 3
- BWWVAEOLVKTZFQ-ISVUSNJMSA-N CHEMBL530 Chemical compound N(/[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)=C\N1CCCCCC1 BWWVAEOLVKTZFQ-ISVUSNJMSA-N 0.000 claims description 3
- FPPNZSSZRUTDAP-UWFZAAFLSA-N Carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 claims description 3
- 229960003585 Cefmetazole Drugs 0.000 claims description 3
- SNBUBQHDYVFSQF-HIFRSBDPSA-N Cefmetazole Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSCC#N)OC)CC=1CSC1=NN=NN1C SNBUBQHDYVFSQF-HIFRSBDPSA-N 0.000 claims description 3
- 108010020487 Cephalosporinase Proteins 0.000 claims description 3
- 229960005091 Chloramphenicol Drugs 0.000 claims description 3
- WIIZWVCIJKGZOK-RKDXNWHRSA-N Chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 3
- 108010028921 Lipopeptides Proteins 0.000 claims description 3
- 206010029803 Nosocomial infection Diseases 0.000 claims description 3
- 229940081192 Rifamycins Drugs 0.000 claims description 3
- 239000004098 Tetracycline Substances 0.000 claims description 3
- 229940040944 Tetracyclines Drugs 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 3
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 3
- 230000000843 anti-fungal Effects 0.000 claims description 3
- 229940121375 antifungals Drugs 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 claims description 3
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 claims description 3
- 125000001153 fluoro group Chemical group F* 0.000 claims description 3
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 3
- 125000002346 iodo group Chemical group I* 0.000 claims description 3
- 229960001890 mecillinam Drugs 0.000 claims description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 150000004291 polyenes Polymers 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 230000002980 postoperative Effects 0.000 claims description 3
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims description 3
- 125000006308 propyl amino group Chemical group 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- ZXDUPDQEFOYLOM-UHFFFAOYSA-O propylideneazanium Chemical group [CH2-]CC=[NH2+] ZXDUPDQEFOYLOM-UHFFFAOYSA-O 0.000 claims description 3
- 150000007660 quinolones Chemical class 0.000 claims description 3
- 235000019364 tetracycline Nutrition 0.000 claims description 3
- 150000003522 tetracyclines Chemical class 0.000 claims description 3
- 229950010206 tigemonam Drugs 0.000 claims description 3
- VZPPEUOYDWPUKO-MQWDNKACSA-N (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxy-2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C=1C=CC=CC=1)OC1=CC=CC=C1 VZPPEUOYDWPUKO-MQWDNKACSA-N 0.000 claims description 2
- JETQIUPBHQNHNZ-NJBDSQKTSA-N (2S,5R,6R)-3,3-dimethyl-7-oxo-6-[[(2R)-2-phenyl-2-sulfoacetyl]amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound C1([C@H](C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)S(O)(=O)=O)=CC=CC=C1 JETQIUPBHQNHNZ-NJBDSQKTSA-N 0.000 claims description 2
- ACAZKHULUUVWCY-JFGNBEQYSA-N (2S,5R,6R)-6-(hexanoylamino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound S1C(C)(C)[C@H](C(O)=O)N2C(=O)[C@@H](NC(=O)CCCCC)[C@H]21 ACAZKHULUUVWCY-JFGNBEQYSA-N 0.000 claims description 2
- GPMSLJIYNWBYEL-TYNCELHUSA-N (2S,5R,6R)-6-[(3-carboxyquinoxaline-2-carbonyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound C1=CC=C2N=C(C(O)=O)C(C(=O)N[C@H]3[C@H]4SC([C@@H](N4C3=O)C(O)=O)(C)C)=NC2=C1 GPMSLJIYNWBYEL-TYNCELHUSA-N 0.000 claims description 2
- KEDAXBWZURNCHS-GPODMPQUSA-N (4R,5S,6S)-3-[(3S,5S)-5-[(3S)-3-[[2-(diaminomethylideneamino)acetyl]amino]pyrrolidine-1-carbonyl]-1-methylpyrrolidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound O=C([C@@H]1C[C@@H](CN1C)SC=1[C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)N1CC[C@H](NC(=O)CN=C(N)N)C1 KEDAXBWZURNCHS-GPODMPQUSA-N 0.000 claims description 2
- GXXLUDOKHXEFBQ-YJFSRANCSA-N (4R,5S,6S)-3-[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)SC(C1)CN1C1=NCCS1 GXXLUDOKHXEFBQ-YJFSRANCSA-N 0.000 claims description 2
- LZKPUSJSJVEXAW-WDXSGGTDSA-N (4S,5R,6S)-3-[7-[1-(2-amino-2-oxoethyl)pyridin-1-ium-3-carbonyl]imidazo[5,1-b][1,3]thiazol-2-yl]-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C([O-])=O)=O)[C@H](O)C)C(SC1=2)=CN1C=NC=2C(=O)C1=CC=C[N+](CC(N)=O)=C1 LZKPUSJSJVEXAW-WDXSGGTDSA-N 0.000 claims description 2
- FLSUCZWOEMTFAQ-PRBGKLEPSA-N (5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(1R,3S)-1-oxothiolan-3-yl]sulfanyl-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1S[C@H]1CC[S@@](=O)C1 FLSUCZWOEMTFAQ-PRBGKLEPSA-N 0.000 claims description 2
- XDZKBRJLTGRPSS-BGZQYGJUSA-N (6R,7R)-3-({[5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl}methyl)-7-{[(2Z)-1-hydroxy-2-(2-imino-2,3-dihydro-1,3-thiazol-4-yl)-2-(methoxyimino)ethylidene]amino}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(C)=C(CC(O)=O)S1 XDZKBRJLTGRPSS-BGZQYGJUSA-N 0.000 claims description 2
- XAKKNLNAJBNLPC-MAYKBZFQSA-N (6R,7R)-3-[(E)-3-[(2-amino-2-oxoethyl)-ethyl-methylazaniumyl]prop-1-enyl]-7-[[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(fluoromethoxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)/C=C/C[N+](C)(CC)CC(N)=O)C([O-])=O)C(=O)C(=N/OCF)\C1=NSC(N)=N1 XAKKNLNAJBNLPC-MAYKBZFQSA-N 0.000 claims description 2
- UJDQGRLTPBVSFN-GZGOMJRCSA-N (6R,7R)-3-[[3-amino-4-(2-aminoethylcarbamoylamino)-2-methylpyrazol-1-ium-1-yl]methyl]-7-[[(2E)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrogen sulfate Chemical compound OS([O-])(=O)=O.CN1C(N)=C(NC(=O)NCCN)C=[N+]1CC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)C(=N\OC(C)(C)C(O)=O)\C=3N=C(N)SN=3)[C@H]2SC1 UJDQGRLTPBVSFN-GZGOMJRCSA-N 0.000 claims description 2
- RTXOFQZKPXMALH-GHXIOONMSA-N (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(N-hydroxyimino)acetamido]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S1C(N)=NC(C(=N\O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 RTXOFQZKPXMALH-GHXIOONMSA-N 0.000 claims description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(2-methyl-5,6-dioxo-1,2,5,6-tetrahydro-1,2,4-triazin-3-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 claims description 2
- NNULBSISHYWZJU-LLKWHZGFSA-N (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 claims description 2
- DKOQGJHPHLTOJR-PUIFZAHNSA-N (6R,7R)-7-[[(2E)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-(6,7-dihydro-5H-cyclopenta[b]pyridin-1-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-PUIFZAHNSA-N 0.000 claims description 2
- WDLWHQDACQUCJR-ZAMMOSSLSA-N (6R,7R)-7-[[(2R)-2-azaniumyl-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-[(E)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)/C=C/C)C(O)=O)=CC=C(O)C=C1 WDLWHQDACQUCJR-ZAMMOSSLSA-N 0.000 claims description 2
- WVPAABNYMHNFJG-QDVBXLKVSA-N 2,2-dimethylpropanoyloxymethyl (6R,7R)-7-[[(Z)-2-(2-amino-1,3-thiazol-4-yl)pent-2-enoyl]amino]-3-(carbamoyloxymethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OCOC(=O)C(C)(C)C)=O)C(=O)\C(=C/CC)C1=CSC(N)=N1 WVPAABNYMHNFJG-QDVBXLKVSA-N 0.000 claims description 2
- XWRCFDRXQPRCCO-FLQNVMKHSA-N 2-[(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carbonyl]oxyethyl-diethylazanium;iodide Chemical compound I.N([C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)OCCN(CC)CC)C(=O)CC1=CC=CC=C1 XWRCFDRXQPRCCO-FLQNVMKHSA-N 0.000 claims description 2
- QYQDKDWGWDOFFU-IUODEOHRSA-N Abbott-48999 Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 claims description 2
- 229950008644 Adicillin Drugs 0.000 claims description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N Ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 2
- 229960003623 Azlocillin Drugs 0.000 claims description 2
- JTWOMNBEOCYFNV-NFFDBFGFSA-N Azlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCNC1=O JTWOMNBEOCYFNV-NFFDBFGFSA-N 0.000 claims description 2
- 229960002699 Bacampicillin Drugs 0.000 claims description 2
- BVGLIYRKPOITBQ-ANPZCEIESA-N Benzathine benzylpenicillin Chemical compound C=1C=CC=CC=1C[NH2+]CC[NH2+]CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 BVGLIYRKPOITBQ-ANPZCEIESA-N 0.000 claims description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 2
- 229960002129 CEFIXIME Drugs 0.000 claims description 2
- 229960000466 CEFPIROME Drugs 0.000 claims description 2
- NPGNOVNWUSPMDP-UTEPHESZSA-N CHEMBL1650818 Chemical compound N(/[C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)OCOC(=O)C(C)(C)C)=C\N1CCCCCC1 NPGNOVNWUSPMDP-UTEPHESZSA-N 0.000 claims description 2
- 229960000662 Carumonam Drugs 0.000 claims description 2
- RRYMAQUWDLIUPV-BXKDBHETSA-N Cefacetrile Chemical compound S1CC(COC(=O)C)=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC#N)[C@@H]12 RRYMAQUWDLIUPV-BXKDBHETSA-N 0.000 claims description 2
- 229960003972 Cefacetrile Drugs 0.000 claims description 2
- 229960005361 Cefaclor Drugs 0.000 claims description 2
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N Cefalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 2
- FUBBGQLTSCSAON-PBFPGSCMSA-N Cefaloglycin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)C)C(O)=O)=CC=CC=C1 FUBBGQLTSCSAON-PBFPGSCMSA-N 0.000 claims description 2
- 229950004030 Cefaloglycin Drugs 0.000 claims description 2
- OLVCFLKTBJRLHI-AXAPSJFSSA-N Cefamandole Chemical compound CN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)[C@H](O)C=3C=CC=CC=3)[C@H]2SC1 OLVCFLKTBJRLHI-AXAPSJFSSA-N 0.000 claims description 2
- 229960003012 Cefamandole Drugs 0.000 claims description 2
- UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 claims description 2
- MLYYVTUWGNIJIB-BXKDBHETSA-N Cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 claims description 2
- 229960001139 Cefazolin Drugs 0.000 claims description 2
- 229960001817 Cefbuperazone Drugs 0.000 claims description 2
- SMSRCGPDNDCXFR-CYWZMYCQSA-N Cefbuperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H]([C@H](C)O)C(=O)N[C@]1(OC)C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 SMSRCGPDNDCXFR-CYWZMYCQSA-N 0.000 claims description 2
- JUVHVMCKLDZLGN-TVNFHGJBSA-N Cefclidin Chemical compound N([C@@H]1C(N2C(=C(C[N+]34CCC(CC3)(CC4)C(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=NSC(N)=N1 JUVHVMCKLDZLGN-TVNFHGJBSA-N 0.000 claims description 2
- 229950011467 Cefclidin Drugs 0.000 claims description 2
- MQLRYUCJDNBWMV-GHXIOONMSA-N Cefetamet Chemical compound N([C@@H]1C(N2C(=C(C)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 MQLRYUCJDNBWMV-GHXIOONMSA-N 0.000 claims description 2
- OKBVVJOGVLARMR-QSWIMTSFSA-N Cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 claims description 2
- 229950001334 Cefluprenam Drugs 0.000 claims description 2
- DYAIAHUQIPBDIP-AXAPSJFSSA-N Cefonicid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)[C@H](O)C=2C=CC=CC=2)CC=1CSC1=NN=NN1CS(O)(=O)=O DYAIAHUQIPBDIP-AXAPSJFSSA-N 0.000 claims description 2
- 229960004489 Cefonicid Drugs 0.000 claims description 2
- 229960004682 Cefoperazone Drugs 0.000 claims description 2
- GCFBRXLSHGKWDP-XCGNWRKASA-N Cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 claims description 2
- 229960001242 Cefotiam Drugs 0.000 claims description 2
- ZJGQFXVQDVCVOK-MSUXKOGISA-N Cefovecin Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)/C(=N/OC)C=2N=C(N)SC=2)CC=1[C@@H]1CCCO1 ZJGQFXVQDVCVOK-MSUXKOGISA-N 0.000 claims description 2
- 229960002682 Cefoxitin Drugs 0.000 claims description 2
- WZOZEZRFJCJXNZ-ZBFHGGJFSA-N Cefoxitin Chemical compound N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)CC1=CC=CS1 WZOZEZRFJCJXNZ-ZBFHGGJFSA-N 0.000 claims description 2
- QDUIJCOKQCCXQY-WHJQOFBOSA-N Cefozopran Chemical compound N([C@@H]1C(N2C(=C(CN3C4=CC=CN=[N+]4C=C3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=NSC(N)=N1 QDUIJCOKQCCXQY-WHJQOFBOSA-N 0.000 claims description 2
- LNZMRLHZGOBKAN-KAWPREARSA-N Cefpimizole Chemical compound N1=CNC(C(=O)N[C@@H](C(=O)N[C@@H]2C(N3C(=C(C[N+]=4C=CC(CCS(O)(=O)=O)=CC=4)CS[C@@H]32)C([O-])=O)=O)C=2C=CC=CC=2)=C1C(=O)O LNZMRLHZGOBKAN-KAWPREARSA-N 0.000 claims description 2
- 229950004036 Cefpimizole Drugs 0.000 claims description 2
- PWAUCHMQEXVFJR-PMAPCBKXSA-N Cefpiramide Chemical compound C1=NC(C)=CC(O)=C1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 PWAUCHMQEXVFJR-PMAPCBKXSA-N 0.000 claims description 2
- WYUSVOMTXWRGEK-HBWVYFAYSA-N Cefpodoxime Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(O)=O)C(=O)C(=N/OC)\C1=CSC(N)=N1 WYUSVOMTXWRGEK-HBWVYFAYSA-N 0.000 claims description 2
- 229960003202 Cefsulodin Drugs 0.000 claims description 2
- DZMVCVMFETWNIU-LDYMZIIASA-N Ceftezole Chemical compound O=C([C@@H](NC(=O)CN1N=NN=C1)[C@H]1SC2)N1C(C(=O)O)=C2CSC1=NN=CS1 DZMVCVMFETWNIU-LDYMZIIASA-N 0.000 claims description 2
- 229960001991 Ceftizoxime Drugs 0.000 claims description 2
- 229960004755 Ceftriaxone Drugs 0.000 claims description 2
- 229940106164 Cephalexin Drugs 0.000 claims description 2
- 229940106196 Cephaloridine Drugs 0.000 claims description 2
- 229940106193 Cephapirin Drugs 0.000 claims description 2
- 229940106192 Cephradine Drugs 0.000 claims description 2
- 229950006467 Ciclacillin Drugs 0.000 claims description 2
- JKXQBIZCQJLVOS-GSNLGQFWSA-N Clometocillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(OC)C1=CC=C(Cl)C(Cl)=C1 JKXQBIZCQJLVOS-GSNLGQFWSA-N 0.000 claims description 2
- 206010067822 Community acquired infection Diseases 0.000 claims description 2
- 229940093912 Gynecological Sulfonamides Drugs 0.000 claims description 2
- 229940041033 Macrolides Drugs 0.000 claims description 2
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 claims description 2
- GPXLMGHLHQJAGZ-JTDSTZFVSA-N Nafcillin Chemical compound C1=CC=CC2=C(C(=O)N[C@@H]3C(N4[C@H](C(C)(C)S[C@@H]43)C(O)=O)=O)C(OCC)=CC=C21 GPXLMGHLHQJAGZ-JTDSTZFVSA-N 0.000 claims description 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N Oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 claims description 2
- TYMABNNERDVXID-DLYFRVTGSA-N Panipenem Chemical compound C([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1S[C@H]1CCN(C(C)=N)C1 TYMABNNERDVXID-DLYFRVTGSA-N 0.000 claims description 2
- 229950011346 Panipenem Drugs 0.000 claims description 2
- NLOOMWLTUVBWAW-HLLBOEOZSA-N Penamecillin Chemical compound N([C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)OCOC(=O)C)C(=O)CC1=CC=CC=C1 NLOOMWLTUVBWAW-HLLBOEOZSA-N 0.000 claims description 2
- 229940056360 Penicillin G Drugs 0.000 claims description 2
- 229940056367 Penicillin V Drugs 0.000 claims description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 2
- HOCWPKXKMNXINF-XQERAMJGSA-N Propicillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(CC)OC1=CC=CC=C1 HOCWPKXKMNXINF-XQERAMJGSA-N 0.000 claims description 2
- 229950009721 Quinacillin Drugs 0.000 claims description 2
- 229950000381 RAZUPENEM Drugs 0.000 claims description 2
- XFGOMLIRJYURLQ-GOKYHWASSA-N Razupenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)SC(SC=1)=NC=1C1=C[C@H](C)NC1 XFGOMLIRJYURLQ-GOKYHWASSA-N 0.000 claims description 2
- IKQNRQOUOZJHTR-UWBRJAPDSA-N Ritipenem Chemical compound S1C(COC(N)=O)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 IKQNRQOUOZJHTR-UWBRJAPDSA-N 0.000 claims description 2
- 229950004286 Ritipenem Drugs 0.000 claims description 2
- 229950000153 Sulopenem Drugs 0.000 claims description 2
- 229960002780 Talampicillin Drugs 0.000 claims description 2
- SOROUYSPFADXSN-SUWVAFIASA-N Talampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(=O)OC2C3=CC=CC=C3C(=O)O2)(C)C)=CC=CC=C1 SOROUYSPFADXSN-SUWVAFIASA-N 0.000 claims description 2
- BVCKFLJARNKCSS-DWPRYXJFSA-N Temocillin Chemical compound N([C@]1(OC)C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C(O)=O)C=1C=CSC=1 BVCKFLJARNKCSS-DWPRYXJFSA-N 0.000 claims description 2
- 229950003816 Tomopenem Drugs 0.000 claims description 2
- KLFSEZJCLYBFKQ-WXYNYTDUSA-N [(3S)-3-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-[(1,5-dihydroxy-4-oxopyridin-2-yl)methoxyimino]acetyl]amino]-2,2-dimethyl-4-oxoazetidin-1-yl] hydrogen sulfate Chemical compound O=C1N(OS(O)(=O)=O)C(C)(C)[C@@H]1NC(=O)C(\C=1N=C(N)SC=1)=N/OCC1=CC(=O)C(O)=CN1O KLFSEZJCLYBFKQ-WXYNYTDUSA-N 0.000 claims description 2
- 229950008560 almecillin Drugs 0.000 claims description 2
- 150000001408 amides Chemical class 0.000 claims description 2
- 229960003022 amoxicillin Drugs 0.000 claims description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 2
- 229960000723 ampicillin Drugs 0.000 claims description 2
- XMQVYNAURODYCQ-SLFBBCNNSA-N apalcillin Chemical compound C1([C@@H](NC(=O)C=2C(=C3N=CC=CC3=NC=2)O)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 XMQVYNAURODYCQ-SLFBBCNNSA-N 0.000 claims description 2
- 229950001979 apalcillin Drugs 0.000 claims description 2
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 claims description 2
- 229960000626 benzylpenicillin Drugs 0.000 claims description 2
- MRMBZHPJVKCOMA-YJFSRANCSA-N biapenem Chemical compound C1N2C=NC=[N+]2CC1SC([C@@H]1C)=C(C([O-])=O)N2[C@H]1[C@@H]([C@H](O)C)C2=O MRMBZHPJVKCOMA-YJFSRANCSA-N 0.000 claims description 2
- 229960003169 biapenem Drugs 0.000 claims description 2
- 125000005997 bromomethyl group Chemical group 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 229960000717 carindacillin Drugs 0.000 claims description 2
- JIRBAUWICKGBFE-MNRDOXJOSA-N carindacillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(=O)OC=1C=C2CCCC2=CC=1)C1=CC=CC=C1 JIRBAUWICKGBFE-MNRDOXJOSA-N 0.000 claims description 2
- UIMOJFJSJSIGLV-JNHMLNOCSA-N carumonam Chemical compound O=C1N(S(O)(=O)=O)[C@H](COC(=O)N)[C@@H]1NC(=O)C(=N/OCC(O)=O)\C1=CSC(N)=N1 UIMOJFJSJSIGLV-JNHMLNOCSA-N 0.000 claims description 2
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 claims description 2
- 229960003525 cefalexin Drugs 0.000 claims description 2
- 229960003866 cefaloridine Drugs 0.000 claims description 2
- 229960004350 cefapirin Drugs 0.000 claims description 2
- 229950004627 cefcapene pivoxil Drugs 0.000 claims description 2
- 229960003719 cefdinir Drugs 0.000 claims description 2
- 229960002142 cefditoren pivoxil Drugs 0.000 claims description 2
- AFZFFLVORLEPPO-UVYJNCLZSA-N cefditoren pivoxil Chemical compound S([C@@H]1[C@@H](C(N1C=1C(=O)OCOC(=O)C(C)(C)C)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1\C=C/C=1SC=NC=1C AFZFFLVORLEPPO-UVYJNCLZSA-N 0.000 claims description 2
- 229950000726 cefetamet pivoxil Drugs 0.000 claims description 2
- 229960001958 cefodizime Drugs 0.000 claims description 2
- ZINFAXPQMLDEEJ-GFVOIPPFSA-N cefoselis Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CN1C=CC(=N)N1CCO ZINFAXPQMLDEEJ-GFVOIPPFSA-N 0.000 claims description 2
- 229950001580 cefoselis Drugs 0.000 claims description 2
- 229950010227 cefotiam hexetil Drugs 0.000 claims description 2
- VVFDMWZLBPUKTD-ZKRNHDOASA-N cefotiam hexetil ester Chemical compound O=C([C@@H](NC(=O)CC=1N=C(N)SC=1)[C@H]1SCC=2CSC=3N(N=NN=3)CCN(C)C)N1C=2C(=O)OC(C)OC(=O)OC1CCCCC1 VVFDMWZLBPUKTD-ZKRNHDOASA-N 0.000 claims description 2
- 229960003391 cefovecin Drugs 0.000 claims description 2
- 229960002642 cefozopran Drugs 0.000 claims description 2
- 229960005446 cefpiramide Drugs 0.000 claims description 2
- 229960005090 cefpodoxime Drugs 0.000 claims description 2
- 229960004797 cefpodoxime proxetil Drugs 0.000 claims description 2
- LTINZAODLRIQIX-FBXRGJNPSA-N cefpodoxime proxetil Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC)C(=O)OC(C)OC(=O)OC(C)C)C(=O)C(=N/OC)\C1=CSC(N)=N1 LTINZAODLRIQIX-FBXRGJNPSA-N 0.000 claims description 2
- 229960002580 cefprozil Drugs 0.000 claims description 2
- SYLKGLMBLAAGSC-QLVMHMETSA-N cefsulodin Chemical compound C1=CC(C(=O)N)=CC=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)[C@@H](C=3C=CC=CC=3)S(O)(=O)=O)[C@H]2SC1 SYLKGLMBLAAGSC-QLVMHMETSA-N 0.000 claims description 2
- 229940036735 ceftaroline Drugs 0.000 claims description 2
- RGFBRLNVZCCMSV-BIRGHMBHSA-N ceftaroline Chemical compound S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OCC)C=2N=C(N)SN=2)CC=1SC(SC=1)=NC=1C1=CC=[N+](C)C=C1 RGFBRLNVZCCMSV-BIRGHMBHSA-N 0.000 claims description 2
- 229950002506 cefteram pivoxil Drugs 0.000 claims description 2
- 229960004366 ceftezole Drugs 0.000 claims description 2
- 229960004086 ceftibuten Drugs 0.000 claims description 2
- 229960002405 ceftolozane Drugs 0.000 claims description 2
- CXHKZHZLDMQGFF-ZSDSSEDPSA-N cefuzonam Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=CN=NS1 CXHKZHZLDMQGFF-ZSDSSEDPSA-N 0.000 claims description 2
- 229950000807 cefuzonam Drugs 0.000 claims description 2
- 229960001351 clometocillin Drugs 0.000 claims description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 2
- 229960002457 epicillin Drugs 0.000 claims description 2
- RPBAFSBGYDKNRG-NJBDSQKTSA-N epicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CCC=CC1 RPBAFSBGYDKNRG-NJBDSQKTSA-N 0.000 claims description 2
- 229950002965 fenbenicillin Drugs 0.000 claims description 2
- 229960005394 flucloxacillin Drugs 0.000 claims description 2
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 2
- 229960003884 hetacillin Drugs 0.000 claims description 2
- DXVUYOAEDJXBPY-NFFDBFGFSA-N hetacillin Chemical compound C1([C@@H]2C(=O)N(C(N2)(C)C)[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 DXVUYOAEDJXBPY-NFFDBFGFSA-N 0.000 claims description 2
- 229940079867 intestinal antiinfectives Sulfonamides Drugs 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 2
- 229960003806 metampicillin Drugs 0.000 claims description 2
- FZECHKJQHUVANE-MCYUEQNJSA-N metampicillin Chemical compound C1([C@@H](N=C)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 FZECHKJQHUVANE-MCYUEQNJSA-N 0.000 claims description 2
- 229960003085 meticillin Drugs 0.000 claims description 2
- 229960000198 mezlocillin Drugs 0.000 claims description 2
- YPBATNHYBCGSSN-VWPFQQQWSA-N mezlocillin Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC=CC=1)C(=O)N1CCN(S(C)(=O)=O)C1=O YPBATNHYBCGSSN-VWPFQQQWSA-N 0.000 claims description 2
- 229960000515 nafcillin Drugs 0.000 claims description 2
- 229940005938 ophthalmologic antiinfectives Sulfonamides Drugs 0.000 claims description 2
- 229960001019 oxacillin Drugs 0.000 claims description 2
- 125000005188 oxoalkyl group Chemical group 0.000 claims description 2
- 229960000596 penamecillin Drugs 0.000 claims description 2
- MIFYHUACUWQUKT-GPUHXXMPSA-N penicillin N Chemical compound OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)CCC[C@@H](N)C(O)=O)C(=O)N21 MIFYHUACUWQUKT-GPUHXXMPSA-N 0.000 claims description 2
- QULKGELYPOJSLP-WCABBAIRSA-N penicillin O Chemical compound OC(=O)[C@H]1C(C)(C)S[C@@H]2[C@H](NC(=O)CSCC=C)C(=O)N21 QULKGELYPOJSLP-WCABBAIRSA-N 0.000 claims description 2
- 229960004331 phenoxymethylpenicillin Drugs 0.000 claims description 2
- 229960004212 pivmecillinam Drugs 0.000 claims description 2
- DWHGNUUWCJZQHO-ZVDZYBSKSA-M potassium;(2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;(2R,3Z,5R)-3-(2-hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound [K+].[O-]C(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21.C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 DWHGNUUWCJZQHO-ZVDZYBSKSA-M 0.000 claims description 2
- 229960004919 procaine Drugs 0.000 claims description 2
- 229960003672 propicillin Drugs 0.000 claims description 2
- 229960004932 sulbenicillin Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 229960001114 temocillin Drugs 0.000 claims description 2
- 229940026752 topical Sulfonamides Drugs 0.000 claims description 2
- GPRBEKHLDVQUJE-VINNURBNSA-N Cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 claims 2
- GSOSVVULSKVSLQ-JJVRHELESA-N Imipenem Chemical compound O.C1C(SCCNC=N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 GSOSVVULSKVSLQ-JJVRHELESA-N 0.000 claims 2
- JFPVXVDWJQMJEE-IZRZKJBUSA-N (6R,7R)-3-[(carbamoyloxy)methyl]-7-[(2Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 claims 1
- HJJDBAOLQAWBMH-YCRCPZNHSA-N (6R,7R)-7-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-{[(1-methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NN=NN1C HJJDBAOLQAWBMH-YCRCPZNHSA-N 0.000 claims 1
- XSPUSVIQHBDITA-RKYNPMAHSA-N (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(5-methyltetrazol-2-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CN1N=NC(C)=N1 XSPUSVIQHBDITA-RKYNPMAHSA-N 0.000 claims 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-O 1-Methylimidazole Chemical compound CN1C=C[NH+]=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-O 0.000 claims 1
- 229940024554 Amdinocillin Drugs 0.000 claims 1
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 claims 1
- 229960003669 Carbenicillin Drugs 0.000 claims 1
- 229960001668 Cefuroxime Drugs 0.000 claims 1
- LQOLIRLGBULYKD-JKIFEVAISA-N Cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 claims 1
- YFAGHNZHGGCZAX-JKIFEVAISA-N Dicloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=C(Cl)C=CC=C1Cl YFAGHNZHGGCZAX-JKIFEVAISA-N 0.000 claims 1
- NONJJLVGHLVQQM-JHXYUMNGSA-N Pheneticillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C)OC1=CC=CC=C1 NONJJLVGHLVQQM-JHXYUMNGSA-N 0.000 claims 1
- ZEMIJUDPLILVNQ-ZXFNITATSA-N Pivampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OCOC(=O)C(C)(C)C)=CC=CC=C1 ZEMIJUDPLILVNQ-ZXFNITATSA-N 0.000 claims 1
- 229960000202 aspoxicillin Drugs 0.000 claims 1
- 229960003791 cefmenoxime Drugs 0.000 claims 1
- SSWTVBYDDFPFAF-DKOGRLLHSA-N ceftibuten dihydrate Chemical compound O.O.S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 SSWTVBYDDFPFAF-DKOGRLLHSA-N 0.000 claims 1
- 229960003326 cloxacillin Drugs 0.000 claims 1
- 229960001585 dicloxacillin Drugs 0.000 claims 1
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- 229940079773 phenethicillin Drugs 0.000 claims 1
- 229960004894 pheneticillin Drugs 0.000 claims 1
- 229960003342 pivampicillin Drugs 0.000 claims 1
- 239000003781 beta lactamase inhibitor Substances 0.000 abstract description 8
- 238000002405 diagnostic procedure Methods 0.000 abstract description 3
- 230000002708 enhancing Effects 0.000 abstract description 2
- 238000001228 spectrum Methods 0.000 abstract description 2
- 239000012453 solvate Substances 0.000 abstract 1
- ZSKVGTPCRGIANV-ZXFLCMHBSA-N IMIPENEM Chemical compound C1C(SCC\N=C\N)=C(C(O)=O)N2C(=O)[C@H]([C@H](O)C)[C@H]21 ZSKVGTPCRGIANV-ZXFLCMHBSA-N 0.000 description 45
- 101700040699 Bli Proteins 0.000 description 43
- LPQZKKCYTLCDGQ-WEDXCCLWSA-N Tazobactam Chemical compound C([C@]1(C)S([C@H]2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1 LPQZKKCYTLCDGQ-WEDXCCLWSA-N 0.000 description 40
- 229960003865 tazobactam Drugs 0.000 description 38
- 101710007828 PCSK2 Proteins 0.000 description 32
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- 230000001580 bacterial Effects 0.000 description 29
- 239000000243 solution Substances 0.000 description 24
- 239000003795 chemical substances by application Substances 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 102100004140 UBAC1 Human genes 0.000 description 19
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- 210000000689 upper leg Anatomy 0.000 description 15
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 101700053141 aex-5 Proteins 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000000725 suspension Substances 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 238000011068 load Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 150000003952 β-lactams Chemical class 0.000 description 11
- 241000588724 Escherichia coli Species 0.000 description 10
- 239000002054 inoculum Substances 0.000 description 10
- 230000000844 anti-bacterial Effects 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- FKENQMMABCRJMK-RITPCOANSA-N Sulbactam Chemical compound O=S1(=O)C(C)(C)[C@H](C(O)=O)N2C(=O)C[C@H]21 FKENQMMABCRJMK-RITPCOANSA-N 0.000 description 8
- 229960005256 Sulbactam Drugs 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- HZZVJAQRINQKSD-PBFISZAISA-N Clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 7
- 241000234221 Klebsiella pneumoniae ATCC BAA-1705 Species 0.000 description 7
- 229960003324 Clavulanic Acid Drugs 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 125000004432 carbon atoms Chemical group C* 0.000 description 6
- GPRBEKHLDVQUJE-QSWIMTSFSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-QSWIMTSFSA-N 0.000 description 6
- 230000001965 increased Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000005429 turbidity Methods 0.000 description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 4
- 229940088710 Antibiotic Drugs 0.000 description 4
- 241000588747 Klebsiella pneumoniae Species 0.000 description 4
- 229940045505 Klebsiella pneumoniae Drugs 0.000 description 4
- 108010087702 Penicillinase Proteins 0.000 description 4
- VZJVWSHVAAUDKD-UHFFFAOYSA-N Potassium permanganate Chemical compound [K+].[O-][Mn](=O)(=O)=O VZJVWSHVAAUDKD-UHFFFAOYSA-N 0.000 description 4
- CSRZQMIRAZTJOY-UHFFFAOYSA-N Trimethylsilyl iodide Chemical compound C[Si](C)(C)I CSRZQMIRAZTJOY-UHFFFAOYSA-N 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 230000005712 crystallization Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 125000002632 imidazolidinyl group Chemical group 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 230000002829 reduced Effects 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 3
- 238000009632 agar plate Methods 0.000 description 3
- 238000002815 broth microdilution Methods 0.000 description 3
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical compound C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 235000013902 inosinic acid Nutrition 0.000 description 3
- 230000001404 mediated Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 125000004193 piperazinyl group Chemical group 0.000 description 3
- 125000003386 piperidinyl group Chemical group 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 3
- 125000001422 pyrrolinyl group Chemical group 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 229940040975 systemic penicillins Beta-lactamase inhibitors Drugs 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- ZKUKMWMSYCIYRD-ZXFNITATSA-N (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (2S,5R,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound O1C(=O)OC(COC(=O)[C@H]2C(S[C@H]3N2C([C@H]3NC(=O)[C@H](N)C=2C=CC=CC=2)=O)(C)C)=C1C ZKUKMWMSYCIYRD-ZXFNITATSA-N 0.000 description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L 7681-57-4 Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 102100015747 BPI Human genes 0.000 description 2
- FFUAGWLWBBFQJT-UHFFFAOYSA-N Bis(trimethylsilyl)amine Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 2
- RRKTZKIUPZVBMF-IBTVXLQLSA-N Brucine Chemical compound O([C@@H]1[C@H]([C@H]2C3)[C@@H]4N(C(C1)=O)C=1C=C(C(=CC=11)OC)OC)CC=C2CN2[C@@H]3[C@]41CC2 RRKTZKIUPZVBMF-IBTVXLQLSA-N 0.000 description 2
- 229920001429 Chelating resin Polymers 0.000 description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N DMSO-d6 Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 241001059013 Escherichia coli J53 Species 0.000 description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 2
- 229950005831 Lenampicillin Drugs 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N Trimethylsilyl chloride Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 238000002814 agar dilution Methods 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000002843 carboxylic acid group Chemical group 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 125000005842 heteroatoms Chemical group 0.000 description 2
- 239000008079 hexane Substances 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000000977 initiatory Effects 0.000 description 2
- 229960000433 latamoxef Drugs 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000000813 microbial Effects 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 238000009740 moulding (composite fabrication) Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 2
- 125000000160 oxazolidinyl group Chemical group 0.000 description 2
- 150000002959 penams Chemical class 0.000 description 2
- 230000036231 pharmacokinetics Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 125000003373 pyrazinyl group Chemical group 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 239000001187 sodium carbonate Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 235000017550 sodium carbonate Nutrition 0.000 description 2
- 239000004296 sodium metabisulphite Substances 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 125000005017 substituted alkenyl group Chemical group 0.000 description 2
- 125000000547 substituted alkyl group Chemical group 0.000 description 2
- 125000004426 substituted alkynyl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 125000004434 sulfur atoms Chemical group 0.000 description 2
- 230000001225 therapeutic Effects 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 230000000699 topical Effects 0.000 description 2
- 125000004665 trialkylsilyl group Chemical group 0.000 description 2
- 239000005051 trimethylchlorosilane Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- MNFORVFSTILPAW-UHFFFAOYSA-N Β-Lactam Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 2
- VQOXZBDYSJBXMA-NQTDYLQESA-N (1S,3R,4E,6E,8E,10E,14E,16E,18S,19R,20R,21S,25R,27R,29R,32R,33R,35S,37S,38R)-3-[(2R,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14, Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- OMDQUFIYNPYJFM-XKDAHURESA-N (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[[(2R,3S,4R,5S,6R)-4,5,6-trihydroxy-3-[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4S,4aS,5aR,12aR)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- SOVUOXKZCCAWOJ-HJYUBDRYSA-N (4S,4aS,5aR,12aR)-9-[[2-(tert-butylamino)acetyl]amino]-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O SOVUOXKZCCAWOJ-HJYUBDRYSA-N 0.000 description 1
- PFVWVVUSAORMBB-VQIMIIECSA-N (6R,7R)-3-[(3-carboxy-4-nitrophenyl)sulfanylmethyl]-8-oxo-7-[(2-thiophen-2-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound O=C([C@@H](NC(=O)CC=1SC=CC=1)[C@H]1SC2)N1C(C(=O)O)=C2CSC1=CC=C([N+]([O-])=O)C(C(O)=O)=C1 PFVWVVUSAORMBB-VQIMIIECSA-N 0.000 description 1
- UHRBTBZOWWGKMK-DOMZBBRYSA-N (6R,7R)-7-[[2-(difluoromethylsulfanyl)acetyl]amino]-3-[[1-(2-hydroxyethyl)tetrazol-5-yl]sulfanylmethyl]-7-methoxy-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound O([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSC(F)F)OC)CC=1CSC1=NN=NN1CCO UHRBTBZOWWGKMK-DOMZBBRYSA-N 0.000 description 1
- GPYKKBAAPVOCIW-HSASPSRMSA-N (6R,7S)-7-[[(2R)-2-amino-2-phenylacetyl]amino]-3-chloro-8-oxo-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;hydrate Chemical compound O.C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CC[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 GPYKKBAAPVOCIW-HSASPSRMSA-N 0.000 description 1
- 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- KEJCWVGMRLCZQQ-DJMWJSSGSA-N 1-acetyloxyethyl (6R,7R)-3-(carbamoyloxymethyl)-7-[[(2E)-2-(furan-2-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(=O)OC(C)OC(C)=O)=O)C(=O)/C(=N/OC)C1=CC=CO1 KEJCWVGMRLCZQQ-DJMWJSSGSA-N 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical compound NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- UIYAXIPXULMHAI-JLGRZTKVSA-N 2,2-dimethylpropanoyloxymethyl (6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(5-methyltetrazol-2-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound S([C@@H]1[C@@H](C(N1C=1C(=O)OCOC(=O)C(C)(C)C)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CN1N=NC(C)=N1 UIYAXIPXULMHAI-JLGRZTKVSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- XLSZMDLNRCVEIJ-UHFFFAOYSA-N 4-methylimidazole Chemical compound CC1=CNC=N1 XLSZMDLNRCVEIJ-UHFFFAOYSA-N 0.000 description 1
- 210000003165 Abomasum Anatomy 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N Amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229940038195 Amoxicillin / Clavulanate Drugs 0.000 description 1
- 229940043312 Ampicillin / Sulbactam Drugs 0.000 description 1
- ODFHGIPNGIAMDK-NJBDSQKTSA-N Azidocillin Chemical compound C1([C@@H](N=[N+]=[N-])C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 ODFHGIPNGIAMDK-NJBDSQKTSA-N 0.000 description 1
- 101700014079 BPI Proteins 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N BRL-49594 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- XCOBLONWWXQEBS-KPKJPENVSA-N BSTFA Chemical compound C[Si](C)(C)O\C(C(F)(F)F)=N\[Si](C)(C)C XCOBLONWWXQEBS-KPKJPENVSA-N 0.000 description 1
- 229960003071 Bacitracin Drugs 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 210000004556 Brain Anatomy 0.000 description 1
- WATFHKRFKDNWQD-UHFFFAOYSA-N C(C1=CC=CC=C1)(C1=CC=CC=C1)OC(=O)C1N2CCC2SC1 Chemical compound C(C1=CC=CC=C1)(C1=CC=CC=C1)OC(=O)C1N2CCC2SC1 WATFHKRFKDNWQD-UHFFFAOYSA-N 0.000 description 1
- RYPRBDZZJFPXLB-UHFFFAOYSA-N C[SiH2]NC(C)=O Chemical compound C[SiH2]NC(C)=O RYPRBDZZJFPXLB-UHFFFAOYSA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L Calcium hydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N Camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- XIURVHNZVLADCM-IUODEOHRSA-N Cefalotin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CC1=CC=CS1 XIURVHNZVLADCM-IUODEOHRSA-N 0.000 description 1
- JSDXOWVAHXDYCU-VXSYNFHWSA-N Cefminox Chemical compound S([C@@H]1[C@@](C(N1C=1C(O)=O)=O)(NC(=O)CSC[C@@H](N)C(O)=O)OC)CC=1CSC1=NN=NN1C JSDXOWVAHXDYCU-VXSYNFHWSA-N 0.000 description 1
- 229960005495 Cefotetan Drugs 0.000 description 1
- SRZNHPXWXCNNDU-RHBCBLIFSA-N Cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 1
- UNJFKXSSGBWRBZ-BJCIPQKHSA-N Ceftibuten Chemical compound S1C(N)=NC(C(=C\CC(O)=O)\C(=O)N[C@@H]2C(N3C(=CCS[C@@H]32)C(O)=O)=O)=C1 UNJFKXSSGBWRBZ-BJCIPQKHSA-N 0.000 description 1
- 229940106195 Cephalothin Drugs 0.000 description 1
- DHSUYTOATWAVLW-WFVMDLQDSA-N Cilastatin Chemical compound CC1(C)C[C@@H]1C(=O)N\C(=C/CCCCSC[C@H](N)C(O)=O)C(O)=O DHSUYTOATWAVLW-WFVMDLQDSA-N 0.000 description 1
- 229960004912 Cilastatin Drugs 0.000 description 1
- 241000157855 Cinchona Species 0.000 description 1
- MYSWGUAQZAJSOK-UHFFFAOYSA-N Ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 1
- 229940090805 Clavulanate Drugs 0.000 description 1
- 108010073254 Colicins Proteins 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 229960004397 Cyclophosphamide Drugs 0.000 description 1
- DOAKLVKFURWEDJ-QCMAZARJSA-N DAPTOMYCIN Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 1
- 229960005484 Daptomycin Drugs 0.000 description 1
- 108010013198 Daptomycin Proteins 0.000 description 1
- LIKFHECYJZWXFJ-UHFFFAOYSA-N Dimethyldichlorosilane Chemical compound C[Si](C)(Cl)Cl LIKFHECYJZWXFJ-UHFFFAOYSA-N 0.000 description 1
- 229960003722 Doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N Doxycycline Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 230000035695 Efflux Effects 0.000 description 1
- 241000588697 Enterobacter cloacae Species 0.000 description 1
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 1
- 241001360526 Escherichia coli ATCC 25922 Species 0.000 description 1
- 229920000926 Galactomannan Polymers 0.000 description 1
- 102000009338 Gastric Mucins Human genes 0.000 description 1
- 108010009066 Gastric Mucins Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- TYZROVQLWOKYKF-ZDUSSCGKSA-N Linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 description 1
- RLSSMJSEOOYNOY-UHFFFAOYSA-N M-Cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N MOPS Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 229960004023 Minocycline Drugs 0.000 description 1
- 229940051867 Moxalactam Drugs 0.000 description 1
- FABPRXSRWADJSP-MEDUHNTESA-N Moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 description 1
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 1
- MSPCIZMDDUQPGJ-UHFFFAOYSA-N N-methyl-N-(trimethylsilyl)trifluoroacetamide Chemical compound C[Si](C)(C)N(C)C(=O)C(F)(F)F MSPCIZMDDUQPGJ-UHFFFAOYSA-N 0.000 description 1
- NCLIGEZQAPUUQU-UHFFFAOYSA-N NC(=O)C[SiH3] Chemical compound NC(=O)C[SiH3] NCLIGEZQAPUUQU-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 240000007639 Nepenthes mirabilis Species 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 229960003330 Pentetic Acid Drugs 0.000 description 1
- 235000014676 Phragmites communis Nutrition 0.000 description 1
- 229940104641 Piperacillin / tazobactam Drugs 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M Potassium bicarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- ATEBXHFBFRCZMA-VXTBVIBXSA-N RIFABUTIN Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N RIFAMPICIN Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- BTTNOGHPGJANSW-IBGZPJMESA-N Radezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C1=CC=C(C=2C=CC(CNCC=3NN=NC=3)=CC=2)C(F)=C1 BTTNOGHPGJANSW-IBGZPJMESA-N 0.000 description 1
- 229950009965 Radezolid Drugs 0.000 description 1
- 229940081190 Rifampin Drugs 0.000 description 1
- WDZCUPBHRAEYDL-GZAUEHORSA-N Rifapentine Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C(O)=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N(CC1)CCN1C1CCCC1 WDZCUPBHRAEYDL-GZAUEHORSA-N 0.000 description 1
- RXZBMPWDPOLZGW-XMRMVWPWSA-N Roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 description 1
- 229910020008 S(O) Inorganic materials 0.000 description 1
- HELHAJAZNSDZJO-UHFFFAOYSA-L Sodium tartrate Chemical compound [Na+].[Na+].[O-]C(=O)C(O)C(O)C([O-])=O HELHAJAZNSDZJO-UHFFFAOYSA-L 0.000 description 1
- 229960002167 Sodium tartrate Drugs 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L Sodium thiosulphate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- XFALPSLJIHVRKE-GFCCVEGCSA-N Tedizolid Chemical compound CN1N=NC(C=2N=CC(=CC=2)C=2C(=CC(=CC=2)N2C(O[C@@H](CO)C2)=O)F)=N1 XFALPSLJIHVRKE-GFCCVEGCSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K Trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N Zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 Zidovudine Drugs 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 125000005079 alkoxycarbonylmethyl group Chemical group 0.000 description 1
- 125000004849 alkoxymethyl group Chemical group 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000005466 alkylenyl group Chemical group 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960003942 amphotericin B Drugs 0.000 description 1
- 230000002429 anti-coagulation Effects 0.000 description 1
- 230000000845 anti-microbial Effects 0.000 description 1
- 230000000111 anti-oxidant Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000840 anti-viral Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004429 atoms Chemical group 0.000 description 1
- 229960004328 azidocillin Drugs 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 101710023159 blaT-5 Proteins 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000006244 carboxylic acid protecting group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229960002025 cefminox Drugs 0.000 description 1
- 229960002620 cefuroxime axetil Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- XDJYMJULXQKGMM-RVYUQJQSSA-N colistin A Chemical compound CC[C@@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O XDJYMJULXQKGMM-RVYUQJQSSA-N 0.000 description 1
- 230000001332 colony forming Effects 0.000 description 1
- 229940000425 combination drugs Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- OSXYHAQZDCICNX-UHFFFAOYSA-N dichloro(diphenyl)silane Chemical compound C=1C=CC=CC=1[Si](Cl)(Cl)C1=CC=CC=C1 OSXYHAQZDCICNX-UHFFFAOYSA-N 0.000 description 1
- KTQYJQFGNYHXMB-UHFFFAOYSA-N dichloro(methyl)silicon Chemical compound C[Si](Cl)Cl KTQYJQFGNYHXMB-UHFFFAOYSA-N 0.000 description 1
- YDVNLQGCLLPHAH-UHFFFAOYSA-N dichloromethane;hydrate Chemical compound O.ClCCl YDVNLQGCLLPHAH-UHFFFAOYSA-N 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229960003276 erythromycin Drugs 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960002878 flomoxef Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000005643 gamma-butyrolacton-4-yl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxyl anion Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960003907 linezolid Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960001977 loracarbef Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- NBTOZLQBSIZIKS-UHFFFAOYSA-N methoxide Chemical compound [O-]C NBTOZLQBSIZIKS-UHFFFAOYSA-N 0.000 description 1
- 239000005048 methyldichlorosilane Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000000877 morphologic Effects 0.000 description 1
- 229960003702 moxifloxacin Drugs 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 101710023153 nmcA Proteins 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003287 optical Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 125000004430 oxygen atoms Chemical group O* 0.000 description 1
- 125000005633 phthalidyl group Chemical group 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229940094025 potassium bicarbonate Drugs 0.000 description 1
- 239000001184 potassium carbonate Substances 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000000069 prophylaxis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229960000885 rifabutin Drugs 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 229960002599 rifapentine Drugs 0.000 description 1
- 229960005224 roxithromycin Drugs 0.000 description 1
- 238000010583 slow cooling Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000003068 static Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 229960004089 tigecycline Drugs 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- PPDADIYYMSXQJK-UHFFFAOYSA-N trichlorosilicon Chemical group Cl[Si](Cl)Cl PPDADIYYMSXQJK-UHFFFAOYSA-N 0.000 description 1
- SIOVKLKJSOKLIF-CMDGGOBGSA-N trimethylsilyl (1E)-N-trimethylsilylethanimidate Chemical compound C[Si](C)(C)OC(/C)=N/[Si](C)(C)C SIOVKLKJSOKLIF-CMDGGOBGSA-N 0.000 description 1
- 239000011778 trisodium citrate Substances 0.000 description 1
- 235000019263 trisodium citrate Nutrition 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Abstract
Described herein are compounds and their use in the treatment of infections. The compound of formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, solvates, pharmaceutically acceptable salts and pharmaceutical compositions described herein are also useful as ß -lactamase inhibitors, which restore or enhance the antibiotic spectrum of a suitable antibiotic agent. The compounds of formula (I) act as inhibitors of ß-lactamases. These compounds restore/potentiate the activities of ß-lactam antibiotics against carbapenemases. These compounds find use in diagnostic method for detecting ß-lactamases.
Description
Described herein are the use of β-lactam compounds as β-lactamase inhibitor, their analogs, dérivatives, tautomeric forms, stereoisomers, poiymorphs, solvatés, pharmaceutically acceptable salts, esters, prodrugs and métabolites thereof, for treating bacterial infections in combination with suitable antibiotic. The pharmaceutical compositions of these compounds for treating bacterial infections are described. The compounds described herein are used as diagnostic reagent for the détection of βlactamases.
Background
The β-lactam type antibiotics, namely pénicilline, cephalosporins, carbapenems, monobactams are frequently used antibiotics. It is known that βlactamases produced by microorganisms hydrolyze the p-iactam ring thereby deactivating antibiotic activity. In order to inhibit the β-lactamases, β-lactamase inhibitors are administered in combination with antibiotics. These inhibitors fonction by binding to the β-lactamase enzymes more efficiently than the β-lactam antibiotic itself. This combination helps the antibiotic to exert its antibiotic effect without being degraded by the β-lactamase enzymes. Several antibiotic/p-lactamase inhibitor combinations exist in the market for example, Ampicillin/Sulbactam, Amoxicillin/Clavulanate, Ticarcillin/Clavulanate, Piperacillin/Tazobactam, etc. These β-lactam/p-lactamase inhibitor combination antibiotics are being used for the treatment of infections caused by bacteria producing β-lactamases excepting especially carbapenemases and inhibitor-resistant β-lactamases in the community and in the hospital setting.
A growing problem by the widespread use of antimicrobiais especially βlactam antibiotics is in the development of antimicrobial résistance. A major cause for antibiotic résistance is due to β-lactamases (e.g., carbapenemases, cephaiosporinases, penicillinases, ESBLs, inhibitor-resistant β-lactamases, etc). Among many known βlactamases, Carbapenemases (e.g., KPC, Sme, NMC-A, IMI, etc.) are recently identified, which are capable of hydrolyzing ail classes of β-lactam antibiotics (Drawz, S.M. and Bonomo, R.A. Clin. Microbiol. Rev. 2010, 23(l), 160-201). These enzymes are known for their rôle in multidrug résistance (MDR). In view of the pressing need
lactamases, our research efforts in identifying potential BLIs resulted in the compound of formula (1).
To address the need for proper diagnostic method for spécifie détection of βiactamases, diagnostic method was identified using the compounds of formula (I).
Among many β-lactamase înhibitors that are known in the literature, compounds of formula (A) are disclosed in US 4,562,073,
COOR1 wherein R1 is hydrogen or trialkylsilyl; R2 is hydrogen, trialkylsilyl or COOR2’ wherein R2' is hydrogen, Ci.1R alkyl, C2.7 alkoxymethyl, C3.8 alkylcarbonyloxymethyl, C4-9 alkylcarbonyloxyethyl, (C5.7 cycioalkyl)carbonyloxymethyl, C9-14 benzylcarbonyloxyalkyl, alkoxycarbonylmethyl, C4.9 alkoxycarbonylethyl, phthalidyl, crotonolacton-4-yl, gamma-butyrolacton-4-yl, halogenated alkyl substituted with 1 to 3 halogen atoms, alkoxy- or nitro-substîtuted or unsubstituted benzyl, benzhydryl, tetrahydropyranyl, dimethylaminoethyl, dimethylchlorosilyl, trichlorosilyl, (5-substituted C]_6 alkyl or phenyl or unsubstituted-2-oxo-l,3-dioxoden4-yl)methyl, Cg-i3 benzoyloxyalkyl or group for form ing a pharmaceutically acceptable 20 sait; and R3 has the same meaning as above R2'
Our patent, US 7,687,488 B2 (Indian équivalent IN 1217CHE2006) disclosed compounds of the formula (B). These compounds were shown to potentiate the
wherein A = C or N; Het is a three- to seven-membered heterocyclic ring; R1 represents carboxylate anion or -COOR4 wherein R4 represents hydrogen, carboxylic acid protecting group or a pharmaceutically acceptable sait; R2 and R3 may be same or different and independently represent hydrogen, halogen, amino, protected amino or optionally substituted alkyl, alkenyl, alkynyl and the like; R is represented by substituted or unsubstituted alkyl, alkenyl, aryl, aralkyl, cycloalkyl, oxo, heterocyclyl, heterocyclylalkyl groups.
There is a widespread need for β-lactamase inhibitors which are capable of inhibiting the β-lactamase enzymes, in particular, carbapenemases producing multidrug résistant bacteria. Moreover, there is a unmet medical need for combination drugs in antibiotics, specifically β-lactam antibiotics and β-lactamase inhibitors which overcome the bacterial résistance.
Objectives
One objective herein is to use the β-iactam compounds of the formula (I) as βiactamase inhibitor in combination with suitable antibiotics for treating infection caused by bacteria producing β-lactamases tike carbapenemases, cephalosporinases, penicillinases, ESBLs, inhibitor-resistant β-lactamases, ESBLs and the like.
Another objective herein is to provide a pharmaceutical composition with the compounds of formula (I) in combination with suitable antibiotics.
Yet another objective herein is to provide a method of treating or preventing bacterial infection in a host, typically an animal and most typically a human, including administering to the host a therapeutic amount of compound of formula (I) or a pharmaceutically acceptable sait and/or prodrug therein along with β-Iactam antibiotics.
Another objective herein is to provide a diagnostic reagent for the détection of β-lactamases. The said β-lactamases belong to the families of KPC (e.g., K.PC-2, KPC-3) & ESBL (e.g., SHV18) producing Enterobacteriaceae.
One more objective herein is to restore/potentiate the activity of antibiotics especially β-lactam antibiotics such as Penicillins, Cephalosporins, Carbacephem, Oxacephem, Carbapenems, Penams, Cephamycins, Penems and Monobactams towards carbapenemases and ESBLs by combining with compound of formula (I).
It is therefore an object of the présent invention to provide a compound for inhibiting β-lactamase; and/or a pharmaceutical composition comprising said compound; and/or an improved method for inhibiting β-lactamase in a cell; and/or an improved method for the treatment and/or prévention of a condition mediated by βlactamase; and/or an improved method for the treatment and/or prévention of a bacterial infection along with β-lactam antibiotic; and/or to restore/potentiate the activity of antibiotics; or at least to provide the public with a useful choice.
Su m mary
Described herein is a method or use of compound of formula (I), their dérivatives, analogs, tautomeric forms, stereoisomers, poiymorphs, solvatés, pharmaceutically acceptable compositions, métabolites, prodrugs, pharmaceutically acceptable salts and esters thereof;
In particular, provided herein are compound of formula (1), their dérivatives, analogs, tautomeric forms, stereoisomers, poiymorphs, solvatés, métabolites, prodrugs, hydrates, pharmaceutically acceptable salts and esters, for use in the inhibition of β-lactamases comprising carbapenemases, cephalosporinases, penicillinases, ESBLs, inhibitor-resistant β-lactamases, produced by bacteria; potentiating/restoring the activity of antibiotics, comprising administering a therapeutically effective amount of compound of formula (I), to a subject in need thereof; wherein A = CorN;
Het represents substituted or unsubstituted three- to seven-membered heterocyclic ring; R1 represents carboxylate anion or -COOR4; wherein R4 represents hydrogen, , C|Côalkyl, Ce-Cioaryl, C6-CioarylC|-C6alkyl methoxybenzyl, nitrobenzyl, silyl, diphenylmethyl, proxetil, axetil, cilexetil, pivoxil, hexetil, daloxate or a pharmaceutically acceptable sait; R2 and R3 may be same or different and îndependently represent hydrogen, halogen, amino, protected amino selected from the group consisting of tritylamino, acylamino such as phenylacetylamino, phenoxyacetylamino and benzoyiamino or optionally substituted Cj-Cealkyl, C2C^alkenyl and C2-C6alkynyl;
R represents substituted or unsubstituted Ci-C^alkyl, Q-Cealkenyl, Ce-Cioaryl, C$CI0aryiCi-Côalkyl, Cî-Cncycloalkyl, oxo, heterocyclyl and heterocyclylalkyl groups. when the groups R, R2 and R3 are substituted, the substituents which may be one or more are selected from lower alkyl (Cj-Cialkyl such as methyl, ethyl, propyl and isopropyl); lower alkoxy (Ci-Qalkoxy such as methoxy, ethoxy and propoxy); lower
alkylthio (Ci-C4alkylthio such as methylthio and ethylthio); lower alkylamino (C<C4alkylamino such as methylamino, ethylamino and propylamino); cyclo(lower)alkyl (Cj-Côcycloalkyl such as cyclopentyl and cyclohexyl); cyclo(lower)alkenyl (C5Cecycloaikenyl such as cyclohexenyl and cyclohexadienyl); hydroxy; halogen (chloro, bromo, fluoro and iodo); amino; protected amino; cyano; nitro; carbamoyl; -CONH Cj-C4aikyl-COO-Cj-C4alkyl; carboxy; protected carboxy; -COO-Ci-C4alkyl; -COheterocyclyl; sulfonyl; sulfamoyl; imino; oxo; amino(lower)alkyl such as aminomethyl, aminoethyl and aminopropyl; halo(lower)alkyl such as trifluoromethyl (CF3), fluoromethyl, fluoroethyl, bromomethyl and difluoromethyl; carboxylic acid and carboxylie acid dérivatives such as hydroxamic acid, ester and amide. Preferred substituents are Ci-C4alkyl, C|-C4alkoxy, Ct-C4alkylthio, Ci-C4alkylamino, hydroxyl, halogen and trihalomethyl. The substituents are further optionally substituted with CiC4alkoxycarbonylCi-C4aikyl, hydroxyCi-C4a)kyl; Ci-C4alkyl, Ce-Cioary), heterocyclyl and esters.
In one aspect, provided herein are compound of formula (II), their dérivatives, analogs, tautomeric forms, stereoisomers, polymorphs, solvatés, métabolites, prodrugs, hydrates, pharmaceutically acceptable salts and esters for use in inhibition of carbapenemases produced by bacteria; potentiating/restoring the activity of antibiotics, comprising administering a therapeutically effective amount of compound of formula (II), to a subject in need thereof;
•R
wherein
L = CorN;
R, R1, R2 and R3 are as defined earlier,
Rs represents hydrogen, Ci-C^lkyl, Ci-C6alkoxy, Cj-Csalkylthio, C[-C6alkylamino, hydroxyl, halogen and trihalomethyl; and m is 0, 1 or 2.
In another aspect, provided herein is compound for use in treating and/or preventing infections caused by carbapenemase producing bacteria, comprising administering therapeutically effective amount of compound of formula (I), to a subject in need thereof.
In yet another aspect, provided herein is compound for use in treating and/or preventing infection caused by carbapenemase producîng bacteria comprising administering therapeutically effective amount of compound of formula (I), in combination with suitable antibiotics to a subject in need thereof.
In yet other aspect, provided herein is the compound for use, for treating infections caused by β-lactamases expressed by gram négative bacteria
In yet other aspecL provided herein is the compound for use, wherein bacteria are selected from Klebsiella pneumoniae and E. coli.
In yet other aspect, provided herein is the compound for use, wherein the carbapenemases are selected from KPC-2 and KPC-3.
In yet another aspect, provided herein is the method of treatment or prévention of infection caused by carbapenemase producîng bacteria comprising administering therapeutically effective amount of compound of formula (I).
Another aspect herein includes détection of β-lactamases expressed by Enterobacteriaceae and non- Enterobacteriaceae.
Yet another aspect herein includes use of compound of formula (I) as a diagnostic reagent for the détection of β-lactamases. The said β-lactamases belong to famîlies of KPC-2, KPC-3 and also ESBLs such as SHV18 producîng Enterobacteriaceae.
In one embodiment, provided herein is pharmaceutical composition, comprising a compound of formula (I), as an active ingrédient to treat or prevent infections caused by carbapenemase producîng bacteria.
In another embodiment, provided herein is pharmaceutical composition comprising a compound of formula (I)» as an active ingrédient to treat or prevent infections caused by carbapenemase producîng bacteria along with
a. one or more compounds of formula (I);
b. one or more antibiotics and
c. one or more pharmaceutically acceptable carrier.
In yet another embodiment, the antibiotics are selected from β-lactam antibiotics.
In yet other embodiment, provided herein are the compounds, (25,35,55)-3Methy l-3-(3-methy l-imidazol-3 -ium-1 -y I methy 1)-4,4,7-trioxo-4-th ia-1 azabicyclo[3.2.0]heptane -2-carboxylate and (25,35,55)-3 -Methy 1-3 -(4-methyl-316437 methyl-imidazol-3-ium-1 -ylmethyl)-4,4,7-trioxo-4-thia-1 -aza-bicycIo[3.2.0]heptane-2carboxylate, their dérivatives, analogs, tautomeric forms, stereoisomers, polymorphe, solvatés, métabolites, prodrugs, pharmaceutically acceptable salts and esters.
In yet another aspect the compounds (25,35,55)-3-Methyl-3-(3-methylimidazol-3-ium-l-ylmethyl)-4,4,7-trioxo-4-thia-1 -azabicyclo[3.2.0]heptane-2carboxylate; (25,35,55)-3-Methyl-3-(4-methyl-3-methyl-imidazol-3-ium-l-ylmethyl)4,4,7-trioxo-4-thia-l-aza-bicyclo[3.2.0]heptane-2-carboxylate and their dérivatives, analogs, tautomeric forms, stereoisomers, polymorphs, solvatés, métabolites, prodrugs, pharmaceutically acceptable salts and esters for use in the inhibition of β-lactamases, without limitation, carbapenemases, cephaîosporinases, penicillinases, ESBLs and inhibitor-resistant β-lactamases.
In yet other aspects, described herein are the compound of formula (I) for use in the treatment and/or prévention of bacterial résistance to an antibiotic.
Brief Description of Figure:
Figure 1: Double Disk Synergy Test for détection of KPC β-lactamases Detailed Description β-Lactam compounds of formula (I),
their dérivatives, analogs, tautomeric forms, stereoisomers, polymorphs, solvatés, their pharmaceutically acceptable compositions, pharmaceutically acceptable salts and esters thereof, for use in the inhibition of carbapenemases produced by bacteria; potentiating/restoring the activity of antibiotics, wherein:
Het is a three to seven membered heterocyclic ring which may hâve suitable substituent(s) and, préférable heterocyclic group such as pyrrolyl, pyrrolinyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, piperidinyl, fiiranyl, thiophenyl, pyrrolidinyl, piperazinyi, oxazolidinyl, thiazolyl, pyrîdaziny), tetrazolyl (e.g. 1Htetrazolyl, 2H-tetrazo!yl, etc.), imidazolidinyl, triazolyl, 1,2,4-oxadiazolyl, 1,3,4oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl and 1,2,5-thîadiazolyl.
The defined heterocyclic groups may optionally be substituted with one or more substituents, suitable substituent(s) such as: lower alkyl (C1-C4 alkyl such as methyl, ethyl and propyl); lower alkoxy (C1-C4 alkoxy such as methoxy, ethoxy and propoxy); lower alkylthio (Ct-C4 alkyithio such as methylthio and ethylthio); lower alkylamino (C1-C4 alkyl ami no such as methylamino, ethylamino and propylamino); cyclo(lower)alkyl (Cs-C6 cycloalkyl such as cyclopentyl and cyclohexyl); cyclo(iower)alkenyl (C5-C6 cycloalkenyl such as cyclohexenyl and cyclohexadienyl); hydroxyl; halogen (chloro, bromo, fluoro and iodo); amino; protected amino; cyano; nitro; carboxy; protected carboxy; sulfamoyl; imino; oxo; amino(lower)alkyl (aminomethyl, aminoethyl and aminopropyl); halogen and trihalomethyl (-CF3). Preferred substituents are C1-C4 alkyl, C1-C4 alkoxy, C1-C4 alkylthio, C]-C4 alkylamino, hydroxyl, halogen and trihalomethyl. The substituents are further optionally substituted.
Typically, the moiety Het is unsubstituted or carries one or more substituents as defined above.
Preferably Het represents a five- to six-membered heterocyclic ring comprising one or two heteroatoms, including the quatemized nitrogen. More preferably, Het is selected from pyrrolyl, pyrrolinyl, imidazolyl, triazolyi, pyrazolyl, pyridyl, pyrimidinyl, pyrazinyl, piperidinyl, furanyl, thiophenyl, pyrrolidinyl, piperazinyl, oxazolidinyl, thiazolyl, pyridazinyl, pyrrolidinyl and imidazolidinyl.
Preferably, Het is an aromatic ring.
More preferably, Het represents five membered heterocyclic ring;
R1 represents carboxylate anion or -COOR4 wherein R4 represents hydrogen, Cfialkyl, Ce-Cioaryl, Ce-CioarylCi-Côalkyl, methoxybenzyl, nitrobenzyl, silyl, diphenylmethyl, proxetil, axetil, cilexetil, pivoxil, hexetil, daloxate or a pharmaceutically acceptable sait;
R2 and R3 independently represent hydrogen, halogen, amino, protected amino such as tritylamino, acylamino such as phenylacetylamino, phenoxyacetylamino and benzoylamino; optionally substituted alkyl, alkenyl or alkynyl;
Preferably R is selected from -(CH2)n-CH3, -(CHîjnCeHs, -(CH2)n-CH=CH2, -CH2-CONH2, -CH2-COO-(Ci-C4alkyl) comprising -CH2COOBu', -(CH2)nCOheterocyclyl, -CH2-CONH-(CH2)n-COOEt, where n is an integer ranging from 0 to 5.
More preferably, R is -fCH2)n-CH3, -(CH2)nC6Hs, -<CH2)n-CH=CH2, -CH2CONH2 or -CH2COOBur.
As used herein, a Ci-Csalkyl group or moiety is a linear or branched alkyl group or moiety containing from l to 6 carbon atoms. Typically a Ci-Cô alkyl group or moiety is a C1-C4 alkyl group or moiety. A C]-C4 alkyl group or moiety is a linear or branched alkyl group or moiety containing from l to 4 carbon atoms. Examples of CiCe alkyl groups and moieties include, without limitation, methyl, ethyl, n-propyl, ipropyl, n-butyl, r-butyl, t-butyl, 3-methyl-butyl, pentyl and hexyl. Examples of Ct-C4 alkyl groups and moieties include, without limitation, methyl, ethyl, n-propyl, r-propyl, n-butyl, ί-butyl and z-butyl. For the avoidance of doubt, where two alkyl moieties are présent in a group, the alkyl moieties may be the same or different, which may be optionally substituted by one or more substituents.
The term “C2-C6alkenyl” refers to an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched chain having about 2 to 6 carbon atoms, which may be optionally substituted by one or more substituents. Preferred alkenyl groups include, without limitation, ethenyl, l-propenyl, 2-propenyl, iso-propenyl, 2-methyl-l-propenyl, l-butenyl and 2-butenyl.
As used herein, a Cs-Cioaryl group or moiety is typically phenyl or naphthyl. Phenyl is preferred.
The term “Ce-CioarylCi-Côalkyl” refers to an aryl group directly bonded to an alkyl group, which may be optionally substituted by one or more substituents. Preferred arylalkyl groups include, without limitation, -CH2C6H5, -C2H4C6H5,CH(CH3)C6H5 and the like.
As used herein, the term “heterocyclyl” refers to a 5 to IO membered heterocyclyl group or moiety is a monocyclic non-aromatic, saturated or unsaturated C5-C10 carbocyclic ring in which one or more, for example l, 2, 3 or 4 of the carbon atoms are replaced with hetero atoms selected from N, O, S, S(O) and S(O)2. Typically, it is a 5 to 6 membered ring. Suitable heterocyclyl groups and moieties include pyrazolidinyl, piperidinyl, piperazinyl, thiomorpholinyl, S-oxothiomorpholinyl, S,S-dioxo-thiomorpholinyl, morpholinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, 1,3-dioxolanyl, 1,4-dioxolyl and pyrazolinyl groups and moieties. Pyrazolidinyl, piperidyl, piperazinyl, pyrazolidinyl, morpholinyl and imidazolidinyl groups and moieties are preferred.
The term “heterocyclylalkyl” refers to heterocyclyl group directly bonded to an alkyl group, which may be substituted or unsubstituted.
The term “Cî-Cucycloalkyl” refers to non-aromatic mono or polycyclic ring system of about 3 to 12 carbon atoms, which may be optionally substituted by one or more substituents. Preferred cycloalkyl groups include, without limitation, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl and perhydronaphthyi.
The term “analog” includes a compound, which differs from the parent structure by one or more C, N, O or S atoms. Hence, a compound in which one of the N atoms in the parent structure is replaced by an S atom is an analog of the former.
The term “dérivative” refers to a compound obtained from a compound according to formula (I), an analog, tautomeric form, stereoisomer, polymorph, hydrate, pharmaceutically acceptable sait or pharmaceutically acceptable solvaté thereof, by a simple chemical process converting one or more functional groups, such as, by oxidation, hydrogénation, alkylation, estérification, halogénation and the like.
The term “stereoisomer” includes isomers that differ from one another in the way the atoms are arranged in space, but whose chemical formulae and structures are otherwise identicai. Stereoisomers include enantiomers and diastereoisomers.
The term “tautomers” include readily interconvertible isomeric forms of a compound in equilibrium. The keto-enol tautomerism is an example.
The term “polymorphs” include crystallographically distinct forms of compounds with chemically identicai structures.
The term “pharmaceutically acceptable solvatés” includes combinations of solvent molécules with molécules or ions of the soluté compound.
Représentative compounds (1-13) exhibiting β-lactamase inhibitory properties include but not limited to:
1. l-{[(25,35,5A)-2-Carboxy-3~methyl-4,4,7-trioxo-4-thia*l-azabicyclo[3.2.0]hept-3yl]methyl}-3-methyl-177-1,2,3-triazol-3-ium;
2. l-{[(25,3Y,57?)-2-Carboxy-3-methyl-4,4,7-trioxo-4-thia-l-azabicyclo[3.2.0]hept-3yl] methyl} -3-ethyl-7/7-l ,2,3-triazol-3-ium;
3. 1 -{[(2S,3S,57î)-2-Carboxy-3-methyM,4,7-trioxo-4-thia-l -azabicyclo[3.2.0]hept-3yl]methyl}-3- n-propyl-J H-1,2,3-triazoi-3-ium;
4. 1-( [(25,35,57?)-2-Carboxy-3-methyl-4,4,7-trioxo-4-thia-l -azabicycIo[3.2.0]hept-3yl]methyl}-3- allyl-/W-l ,2,3-trîazol-3-ium;
5. 1-(((25, 35,5/?)-2-Carboxy-3-methyl-4,4,7-trioxo4-thia-l-azabicyclo[3.2.0]hept-3yl]methyl}-3-(2-amino-2-oxoethyl)-77f-l,2,3-triazol-3-ium and the corresponding acid;
6. I-{[(25,35,57?)-2-Carboxy-3-methyl-4,4,7-trioxo-4-thia-l -azabicyclo[3.2.0]hept-3yl]methyl}-3-(2-i-butoxy-2-oxoethyl)-7/f-l,2,3-triazol-3-ium and the corresponding acid;
7. 1-(((25,35,5/ï)-2-Carboxy-3-methyl-4,4,7-trioxo-4-thia-l-azabicyclo[3.2.0]hept-3yl]methyl}-3-(2-morpholin-4-yl-2-oxoethyl)-7J7-l,2,3-triazol-3-ium and the corresponding acid;
8. 1-(((25,35,5Â)-2-Carboxy~3-methyl-4,4,7-trioxo-4-thia-l-azabicyclo[3.2.0]hept-3yl]methyl}-3-(2[(2-ethoxy-2-oxoethyl)amino]-2-oxoethyl)-777-l,2,3-triazol-3-ium and the corresponding acid;
9. l-{[(25,35,5A)-2-Carboxy-3-methyl-4,4,7-trioxo-4-thia-l-azabicyclo[3.2.0]hept-3- y Ijmethy 1} -3-(2-[(3 -ethoxy-3 -oxopropy l)amino]-2-oxoethy 1 ,2,3-triazol-3 ium and the corresponding acid;
10. l-{[(25,35,57?)-2-Carboxy-3-methyl-4,4,7-trioxo4-thia-l-azabicyclo[3.2.0}hept-3yl]methyl}-3-(2-{[l-(ethoxycarbonyl)-2-hydroxypropyl]amino}-2-oxoethyl)-777l,2,3-triazol-3-ium and the corresponding acid;
11. 1 - {[(25,35,57?)-2-Carboxy-3 -methy 1-4,4,7-trioxo-4-thia-1 -azabicyclo[3.2.0]hept-3yl]methyl}-3-ben2yl-177-l,2,3-triazol-3-ium and the corresponding acid;
12. (2S,35,57î)-3-Methyl-3-(3-rnethyl-irnidazol-3-iurn- ] -ylmethyl)-4,4,7-trioxo-4-thial-azabicyclo[3.2.0]heptane-2-carboxylate and the corresponding acid; and
13. (2.S',3A',57?)-3-Methyl-3-(4-methyl-3-methyi-imidazol“3~ium~ 1 -ylrnethyl)-4,4,7trioxo-4-thia-l-aza-bicyclo[3.2.0]heptane-2-carboxylate and the corresponding acid.
These compounds (1 to 11) were prepared by foilowing the procedures provided in US 7,687,488 (Indian équivalent IN 1217CHE2006).
The compounds 12 and 13 are prepared according to reaction scheme as shown below:
wherein Het is
Compound of formula (IV) was obtained by the reaction of compound of formula (VI) with the compound of formula (V) in Step-1. In Step-2, the compound of formula (IV) was converted to the compound of formula (III). The conversion of compound of formula (III) to a compound of formula (I) may be carried out using silylatîng agent selected from hexamethyldisilazane (HMDS), trimethylchlorosilane (TMCS), trimethylsilyl iodide (TMSI), N,O-bis-(trimethylsilyl)-acetamide (BSA), methyltrimethylsilyltrifluoroacetamide (MSTFA), N,Obis(trimethylsilyl)trifluoroacetamide (BSTFA), methyldichlorosilane, dimethyldichlorosilane, diphenyldichlorosilane, N-methylsilylacetamide (MSA), bistrimethylsiiylurea and the like in the presence of solvents like acetone, methanol, tetrahydrofuran, chloroform, dichloromethane, dichloroethane, ethyl acetate, N,Ndimethylformamide (DMF), Dimethylacetamide (DMAc) and the like or a mixture thereof. The compound of formula (1) was obtained by the reaction of compound of 20 formula (III) with a suitable R-X (X = halogen).
The β-lactam compounds described herein are preferably formed as inner salts. When the représentative substitution on R is carboxylic acid or amino group, it may be further converted to pharmaceutically acceptable salts. Bases used for making salts of carboxylic acid groups are selected from base such as sodium hydroxide, sodium 25 methoxide, sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, calcium hydroxide, magnésium hydroxide and the like, in solvents like ether, tetrahydrofuran, methanol, /-butanol, dioxane, isopropanol, éthanol, etc. Mixture of solvents may be used. Acid addition salts could also be prepared using appropriate acid.
The stereoisomers of the compounds forming part of this invention may be prepared by using reactants in their single enantiomeric form, in the process wherever possible or by conducting the reaction in the presence of reagents or catalysts in their single enantiomeric form or by resolving the mixture of stereoisomers by conventional methods. Some of the preferred methods include use of microbial resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid, tartane acid, lactic acid and the like, wherever applicable or by using chiral bases such as brucine, cinchona alkaloids, their dérivatives and the like.
Prodrugs of the compounds of formula (I) are also contemplated by this invention. A prodrug is an active or inactive compound that is modified chemically through in-vivo physiological action, such as hydroiysis, metabolism and the like, into a compound of this invention following administration of the prodrug to a patient. The suitability and techniques involved in making, using prodrugs are well known by those skilled in the art.
Various polymorphs of compound of general formula (I) may be prepared by crystallization of compound of formula (I) under different conditions known in the prior art. For example, using different solvents commonly used or their mixtures for recrystallization; crystallizations at different températures; various modes of cooling, ranging from very fast to very slow cooling during crystallizations. Polymorphs may also be obtained by heatîng or melting the compound followed by graduai or fast cooling. The presence of polymorphs may be determined by Solid Probe NMR Spectroscopy, IR Spectroscopy, Differential Scanning Calorimetry, Powder X-ray Diffraction or such other techniques.
Pharmaceutically acceptable solvatés of the compounds of formula (I) may be prepared by conventional methods such as dissolving the compounds of formula (I) in solvents such as water, methanol, éthanol, mixture of solvents such as acetone: water, dioxane: water, N,N-dimethyiformamide:water and the like, preferably water and recrystallizing by using different crystallization techniques.
It should be noted that compounds described herein may contain groups that may exist in tautomeric forms and though one form is named, described, displayed and/or claimed herein, ail the forms are intended to be inherently included in such name, description, display and/or claim.
The β-lactam compounds disclosed herein in combination with a β-lactam antibiotic are useful for the treatment of microbial infections in humans and other warm blooded animais, under both parentéral, topical and/or orai administration. In addition to the compounds of formula (I), the pharmaceutical compositions may also contain or be co-administered with one or more known drugs selected from other clinically useful antibiotic agents such as Penicillins (Piperacillin, Ticarcillin and the like), Cephalosporins (Ceftazidime, Cefmetazole, Cefotaxime and the like), Penems (Faropenem, Meropenem, Ertapenem and the like), Carbacephem (Loracarbef and the like), Oxacephem (Moxalactam, Latamoxef, Flomoxef and the like), Cephamycins (Cefotetan and the like) Monobactams (Aztreonam, Tigemonam and the like), Aminoglycosides (Streptomycin, Gentamicin, Amikacin and the like), Bacteriocins (Colicins, Microcins and the like), Quinolones (Ciprofloxacin, Moxifloxacin and the like), Sulfonamîdes (Sulfamethoxazole and the like), Macrolïdes (Erythromycin, Roxithromycin, Azithromycîn and the like), Tetracyclines (Doxycycline, Minocycline and the like), Glycylcyclines (Tigecycline and the like), Oxazolidinones (Linezolid, Torezolid, Radezolid and the like), Lipopeptides (Daptomycin and the like), Polypeptides (Actinomycin, Bacitracin, Colistin, Polymixin B and the like), Polyene antifungals (Natamycîn, Nystatin, Amphotericin B and the like), Rifamycins (Rifampicin, Rifabutin, Rifapentine and the like), Chloramphenicol and the like or dérivatives thereof.
Antibiotics include Penicillins, Cephalosporins, Carbacephems, Oxacephems, Carbapenems, Penams, Cephamycins, Penems, Monobactams or a combination thereof.
Pencillins include, but are not limited to, Arndinocillin (Mecillinam), Amoxicillin, Ampicillin, Amylpenicillin, Apalcillin, Aspoxiciliin, Azidocillin, Azlocillin, Bacampicillin, Carbeniciliin, Carindacillin, Clometocillin, Cloxaciilin, Cyclacillin (Ciclacillin), Dicioxacillin, Epicillin, Fenbenicillin, Floxacillin (flucloxacillin), Hetacillin. Lenampicillin, Metampicillin, Methicillin, Mezlocillin, Nafcillin, Oxacillin, Penamecillin, Penethecillin, Penicillin G (Procaine Pencillin), Penicillin N, Penicillin O, Penicillin V (Phenoxymethyl Penicillin), Phenethicilün, Piperacillin, Pivampîcillin, Propicillin, Quinacillin, Sulbenicillin, Talampicillin, Temocillin, Ticarcillin, Pivmecillinam, Benzathine Penicillin, Benzyl Penicillin, Coamoxiclav, Lenampicillin or a combination thereof.
Cephalosporins include but not limited to Cephaloridin, Cephradine, Cefoxitin, Cephacetril, Cefoperazone, Cefinenoxime, Cephaloglycin, Cefonicid, Cefodizime, Cefpirome, Cefpiramide, Cefozopran, Cefoselis, Cefluprenam, Cefpimizole, Cefclidin, Cefpodoxime axetil, Cefteram pivoxil, Cefcapene pivoxil, Ceftobiprole, Ceftaroline, Cefquinome, Ceftîofur, Cefovecin, Cefadroxil, Cefalonium, Cefepime, Cefotaxime, Ceftazidime, Cefetamet pivoxil, Cefditoren pivoxil, Cephaloridine, Ceftazidime, Ceftriaxone, Cefbuperazone, Cephalothin, Cephazolin, Cephapirin, Ceftezole, Cefamandole, Cefotiam , Cefotiam hexetil, Cefiiroxime, Ceftizoxime, Cefinenoxime, Cefuzonam, Cefsulodin, Cefmetazole, Cefminox, Cephalexin, Cefradine, Cefaclor, Cefadroxil, Cefalonium, Cefprozil, Cefuroxime axetil, Cefixime, Cefpodoxime proxetil, Ceftibuten, Cefdinir, CXA-l0l(FR264205) or a combination thereof;
Penems include, without limitation, Faropenem and Carbapenems include, without limitation Meropenem, Ertapenem, Doripenem, Biapenem, Panipenem, Ritipenem, Tebipenem, Tomopenem, Sulopenem, Razupenem, Imipenem, ME1036, SM216601 or a combination thereof.
Monobactams include, without limitation, Aztreonam, Carumonam, Tigemonam, BAL19764, BAL30072 or a combination thereof.
β-lactam antibiotics in combination with compounds of the formula (I) may also be co-administered with Aminoglycosides, Bacteriocins, Quinolones, Sulfonamides, Macrolides, Tetracyclines, Glycylcyclines, Oxazolidinones, Lipopeptides, Polypeptides, Rifamycins, Chloramphenicol, Polyene antifungals and dérivatives thereof.
Compounds of the formula (I) may also contain or be co-administered with bactericidal/permeability-increasing protein product (BPI) or efflux pump inhibitors to improve activity against gram négative bacteria and bacteria résistant to antîmicrobial agents. Antiviral, antiparasitic, antifungal agents and other antibiotics can also be administered in combination with the inhibitor compounds of formula (I). The compound of formula (1) with a suitable antibiotic combination can be used for treating patients with bacteria! infections, preoperative patients, postoperative patients, patients in intensive care unit (ICU), patients with nosocomial infections and veterinaries.
The pharmaceutical composition may be in the forms normally employed, such as tablets, capsules, pills, granules, powders, syrups, lozenges, solutions, suspensions, aérosols, transdermal patches, topical creams and ointments and the like, may contain
ΙΟ flavoring agents, sweeteners, etc. in suitable solid or liquid carriers or diluents or in suitable stérile media to form injectable solutions or suspensions. The pharmaceutical composition may also contain pharmaceutically acceptable carrier that are known in the prior art.
The compounds can be lyophilized alone or in combination with antibiotic compounds/agents as described above optionally including any agents. The agents include complexing agents or anticoagulants, antioxidants, stabilizers, aminoglycosides, pharmaceutically acceptable salts and the like or mixtures thereof. The lyophilization can be performed for dilute solutions or concentrated solutions depending on the required quality of the final product. Prior to lyophilization or fireeze-drying or thawing, the lyophilizate can be degassed to optimum concentration of gas. The compounds can be filtered under stérile condition. Appropriate fllters such as ultrafiltration could also be used in order to reduce the levels of galactomannan substantially. The compounds of formula (I) could also be physically blended with a suitable antibiotic agent.
The compound of formula (I) can also be used for treating infections caused by bacteria producîng β-lactamases, in particular, K.PC-2.
In addition to the compound of formula (I), the pharmaceutical composition may also contain buffers like sodium citrate, sodium acetate, sodium tartrate, sodium carbonate, sodium bicarbonate, morpholinopropanesulfonic acid, other phosphate buffers and the like and chelating agents like ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid, hydroxyethylenediaminetriacetic acid, nitrilotriacetic acid, 1,2-diaminocycIohexanetetraacetic acid, bis(2aminoethyl)ethyleneglycoltetraacetic acid, 1,6-hexamethylenediaminetetraacetic acid and the like or pharmaceutically acceptable salts thereof. Compounds of formula (I) are useful in treating or preventing a bacterial infection in a host, typically an animal and most typically a human, including administering to the host a therapeutic amount of compound of formula (I) or a pharmaceutically acceptable sait and/or prodrug therein along with β-lactam antibiotic.
The term “prophylaxis” or “prévention” means preventing the disease, i.e., causing the clinical symptoms of the disease not to develop.
The term “treatment*'/“treating” means any treatment of a disease in a mammal, including: (a) Inhibiting the disease, i.e., slowing or arrestîng the development of clinical symptoms; and/or (b) Relieving the disease, i.e., causing the régression of clinical symptoms.
The term “therapeutically effective amount” or “effective amount” refers to that amount of a compound or mixture of compounds of formula (I) that is sufficient to effect treatment, as defined below, when administered aione or in combination with 10 other thérapies to a mammal in need of such treatment.
The term potentiating refers to the enhancement of the effects of an agent by another agent so that the total effect is greater than the sum of the effects of either agent.
The term “compound(s) for use” as used herein embrace any one or more of the 15 following: (1) use of compound(s), (2) method of use of compound(s), (3) use in the treatment of, (4) the use for the manufacture of pharmaceutical composition / médicament for treatment/treating or (5) method of treatment / treating/ preventing / reducing t inhibiting comprising administering an effective amount of compound of formula (I) to a subject in need thereof.
The term ‘subject’ refers to patients with bacterial infections, preoperative patients, postoperative patients, patients in ICU, patients with nosocomial infections, community acquired infections and veterinaries.
From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and without departing from the spirit and 25 scope thereof make various changes and modifications of the invention to adapt it to various usages and conditions.
A term once described, the same meaning applies for it throughout the patent. Reference Compound-1 (Compound-1) l-{[(25,3S, 57f}-2-Carboxy-3-niethyl-4,4,7-trioxo-4-thia-l-azabicyclo[3.2.01hept-330 ylJmethyl}-3-methyl-7//-1^23-triazol-3-ium
To a suspension of (25,35,5A)-3 -methyl-7-oxo-3-(lH-1,2,3 -triazol-1 -yImethyl)4-thîa-l-azabicycio-[3.2.0]heptane-2-carboxyiic acid 4,4-dioxide (25 g) in acetone (100 mL) at 25-30 ‘C was added slowly N,O-bis(silyl)acetamide (18.6 g) with stirring.
The reaction mixture was stirred at this température (25-30 °C) for 15-20 minutes. To
the clear solution obtained, methyl iodide (100 mL) was added over a period of 15 minutes and stirred at 25-30 minutes for 24 hours. The precipitated solid was separated by filtration and washed with acetone (25 mL). Wet weight of the solid obtained was 30 g.
The above wet solid was stirred with purified water (300 mL) at 10-15 °C for 2.5 hours. To the resulted reaction mixture was added sodium thiosulfate (0.1 g) and stirred at 10-15 ’C for 10-15 minutes. To the reaction mixture, dichloromethane (300 mL) was added, stirred and the organic layer was separated, The aqueous layer was washed with a solution of Amberlite LA-2 resin (5% solution in dichloromethane twice, followed by dichloromethane twice. To the aqueous solution, actîvated carbon (1 g) was added, stirred for 15 minutes, filtered and washed with purified water (25 mL). The solution was filtered and lyophilized to get the title compound in pure form (10 g). 'H NMR (400 MHz, DMSO-d6) δ ppm: 1.39 (s, 3H), 3.14 (dd, J = 16.0, 1.3 Hz, 1H), 3.55 (dd, J = 16.0, 4.2 Hz, 1H), 3.97 (s, 1H), 4.34 (s, 3H), 5.05 (dd, J = 4.2, 1.3 Hz, 1H), 5.29 (d, J = 14.7 Hz, 1H), 5.42 (d, J = 14.7 Hz, 1H), 8.91 (d, J = 1.3 Hz, 1H), 8.99 (d, J = 1.3 Hz, 1H). Mass m/z: M+1 peak at 315. Alternatively the solution could be subjected to spray-dry ing to yield the title compound.
Compound-12 (IS^S, 5Z?)-3-Methy l-3-(3-methyl-i midazol-3-ium-l-y 1 methyl)-4,4,7-t rioxo-4-th ial-azabicyclo|3.2.0]heptane-2-carboxyIate
Step 1: Préparation of (253^,5/î)-3-(imidazol-l-ylmethyl)-3-methyl-7-oxo-4-thia1-aza-bicyclo [3.2.0] heptane-2-carboxylic acid benzhydryl ester
To a stirred solution of imidazole (1.696 g, 24.9 mmol) in acetonitrile (75 mL) and water (25 mL) was added sodium bicarbonate (4.18 g, 49.8 mmol) and the résultant mass was stirred for 15 minutes. (2S,3S,57ï)-3-Chloromethyl-3-methyl-7oxo-4-thia-l-aza-bicyc!o[3.2.0]heptane-2-carboxylic acid benzhydryl ester (10 g, 24.8 mmol) was added to the above mixture and stirred at 25-30 °C for 24 hours. After the completion of the reaction, the reaction mass was diluted with ethyl acetate and water mixture. The organic layer was separated. The aqueous layer was again extracted with ethyl acetate. The combined organic layer was dried over anhydrous sodium sulphate and concentrated under vacuum to yield crude (23,3S,57Î)-3-(imidazol-l-ylmethyl)-3methyl-7-oxo-4-thia-l-aza-bicyclo[3.2.0]heptane-2-carboxylic acid benzhydryl ester. Yield: 10 g.
Step 2: Préparation of (2333,5^)-3-(imidazol-l-ylmethyl)-3-methyM,4,7-trioxo· 4-thia -l-aza-bicyclo[3.2.0]heptane-2-carboxylic acid benzhydryl ester
The crude (23,33,5A)-3-(imidazo!-l-ylmethyl)-3-methyl-7-oxo-4-thia-l-azabicyclo[3.2.0]heptane-2-carboxylîc acid benzhydryl ester (10 g) obtained in the previous step was dissolved in acetonitrile (50 mL). Acetic acid and water mixture was added to the above solution and was cooled to 0 - 5 °C. To the homogeneous reaction mixture potassium permanganate (14.59 g, 92.3 mmol) was added. Stirring was continued at 0 - 5 °C for another 2 hours. The reaction mass was quenched with sodium metabisulphite solution. The réaction mass was diluted with ethyl acetate and water mixture. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organic layer was neutralised with saturated sodium bicarbonate solution. The organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure. Acetone was added to the residue obtained and stirred for 30 minutes. A white solid precipitated out, which was filtered and dried. Yield: 2.60 g (22.4 %). 'H NMR (400 MHz, DMSO-dé) δ ppm: 1.09 (s, 3H), 3.35 (d, J = 16.0 Hz, 1H), 3.76 (dd, J = 16.0, 2.0 Hz, 1H), 4.42 (d, J = 15.6 Hz, 1H), 4.90 (d, J = 15.6 Hz, 1H), 5.10 (s, 1H), 5,26(m, 1H), 6.89 (s, 2 H), 6.98 (s, 1H), 7.33 - 7.50 (m, 11H). Mass m/z: 466 (M+1).
Step-3: Préparation of (2333,5R)-3-(imidazoI-l-ylmethyl)-3-methyl-4,4,7-trioxo4-thia-l-aza-bicyclo[3.2.0]heptane-2-carboxylic acid (Compound-M)
V
To a solution of (25,35,5JÎ)-3-(imidazol-l-ylmethyl)-3-methyl-4,4,7-trioxo-4thia-l-aza-bicyclo[3.2.0]heptane-2-carboxylic acid benzhydryl ester (900 mg, 1.9 mmol) in methanol (20 mL) was added 10% Pd/C (900 mg w/w) and stirred under hydrogen atmosphère for 2 hours. The reaction mass was filtered and washed with methanol. The filtrate was evaporated under reduced pressure. To the residue was added diethyl ether (30 mL) and stirred for 15 minutes. The white solid precipitated out was filtered and washed with diethyl ether. Yield: 530 mg (91.3 %). lH NMR (400 MHz, DMSO-dé) δ ppm: 1.38 (s, 3H), 3.28 (d, J = 16.4 Hz, IH), 3.68 (dd, J = 16.4,4.4 Hz, IH), 4.51 (d, 15.2Hz, IH), 4.53 (s, IH), 4.84 (d, J = 15.2Hz, IH), 5.14- 5.15 (m, IH), 7.02 (s, IH), 7.25 (s, IH), 7.85 (s, IH). Mass m/z: 300 (M+l).
Step 4: Préparation of (2S0S,5R)-3-methyl-3-(3-methyl-imidazol-3-Îum-ly!methyl)-4,4,7-trioxo-4-thia-l-azabicycIo[3.2.0Jheptane-2-carboxyIate
o.
·/ «Hj
COJ]
To a suspension of (2<S,35,57î)-3-(imidazol-l-ylmethyl)-3-methyl-4,4,7-trioxo4-thîa-l-aza-bicyclo[3.2.0]heptane-2-carboxylic acid (450 mg, 1.5 mmol) in dry acetone (1.8 mL) was added slowly N, O-bis(silylacetamide) (0.93 mL, 3.7 mmol) with stirring. The reaction mass was stirred further for 15 minutes. To the clear solution obtained, methyl iodide (1.8 mL) was added and stirred at 25 - 30 °C for 2 days. The reaction mass was concentrated and diluted with dichloromethane-water. The organic iayer was separated. The aqueous iayer was washed with a solution of Amberlïte LA-2 resin (30% solution in dichloromethane), followed by dichloromethane. The aqueous Iayer was degassed and lyophilized to obtain the title compound. Melting point: 161.37 °C. lH NMR (400 MHz, DiO) δ ppm: 1.53 (s, 3H), 3.47 (dd, J = 16.7, 1.36 Hz, IH), 3.70 (dd, J = 16.7, 4.2 Hz, IH), 3.94 (s, 3H), 4.41 (s, IH), 4.99 (ABquartet, J = 15.4Hz, 2H), 5.09 (m, IH), 7.53 (s, IH), 7.64 (s, IH), 8.99 (s, IH). Mass m/z: 314 (M+l). Compound 13 (25^^J?)-3-Methyl-3-(4-methyl-3-methyl-imidazol-3-iuni-l-ylmethyl)-4,4,7trioxo-4-thia-l-aza-bicyclo[3.2.0]heptane-2-carboxylate
Step 1; Préparation of (25'r3S'^i)-3-(4-methyl-iniidazol-l-ylmethyl)-3-niethyl-7oxo-4-thia-l-aza-bicyclo[3.2.0]heptane-2-carboxylic acid benzhydryl ester
To a stirred solution of (2S,3S,5/î)-3-chloromethyl-3-methyl-7-oxo-4-thia-laza-bicyclo[3.2.0]heptane-2-carboxylicacid benzhydryl ester (3 g, 7.4 mmol) in acetonitrile (22.5 mL)) was added sodium bicarbonate (628 mg, 7.4 mmol), water (7.5 mL) and 4-methyl-imidazole (1.22g, 7.4 mmol). The résultant mass was stirred at 25 30 °C for 42 hours. The reaction mass was diluted with ethyl acetate and water mixture. The organic layer was separated. The aqueous layer was again extracted with ethyl acetate. The combined organic layer was dried over anhydrous sodium sulphate and concentrated under vacuum to yield crude (2S,35',5JÎ)-3-(4-methyIimÎdazol-lylmethyl)-3-methyl-7-oxo-4-thia-l-aza-bicyclo[3.2.0]heptane-2-carboxylic acid benzhydryl ester. Yield: 3.5 g.
Step 2: Préparation of (2S^S'^X)-3-(4-niethyl-imidazol-l-ylniethyl)-3-inethyl4,4,7-trioio-4-thia -l-aza-bicyclo[3.2.0Jheptane-2-carboxylic acid benzhydryl »
ester.
0A ,.O
CH,
The crude (25,3S,5/?)-3-(4-methyl-imidazol-l-yImethyl)-3-methyl-7-oxo-4thia-l-aza-bicyclo[3.2.0]heptane-2-carboxylic acid benzhydryl ester (3.5 g, 7.8 mmol) from the previous step was dissolved in acetonitrile (18 mL). Acetic acid (18 mL) and water (9 mL) mixture was then added to the above solution and cooled to 0 - 5 °C. To the homogeneous reaction mixture potassium permanganate (2.47 g, 15.6 mmol) was added. Stirring was continued at 0 - 5 °C for another 2 hours. The reaction mass was then quenched with sodium metabisulphite solution and diluted with ethyl acetate and water. The organic layer was separated and the aqueous layer was extracted with ethyl acetate. The combined organic layer was neutralised with saturated sodium bicarbonate solution. The organic layer was dried over anhydrous sodium sulphate and concentrated under reduced pressure. Purification of the crude compound using silicagel column chromatography (gradient elution with 40-50% ethyl acetate in hexane) yielded the pure compound as a colourless solid. Yield: 350 mg (10 %). *H
ΙΟ
NMR (400 MHz, CDCI3, δ ppm): 1.00 (s, 3H), 2.17 (s, 3H), 3.50 (dd, J = 16.2 Hz, 1.8 Hz, 1H), 3.57 (dd, J = 16.2 Hz, 4.1 Hz, 1 H), 4.24 (d, J = 15.3 Hz, 1H), 4.50 (s, 1H), 4.61-4.62 (m, 1H), 6.53 (s, 1H), 6.99 (s, 1H ),7.05 (s, 1H) 7.32-7.49 (m, 10H).
Step 3: Préparation of (25,3>S\5/?)-3-inethyl-3-(4-methyl-3-methyl-imidazol-3-iuml-ylmethyl)-4,4,7-trioxo-4-thia-l-aza-bicyclo[3.2.0]heptane-2-carboxylic acid benzhydryl ester
Ι5
έο^Η
Το a suspension of (2S,35,5/i)-3-(4-methyl-imidazol-l-ylmethyl)-3-methyl4,4,7-trioxo-4-thia-l-aza-bicyclo[3.2.0]heptane-2-carboxylic acid benzhydryl ester (350 mg, 0.6 mmol) in dry acetone (4 mL) was added methyl iodide (4 mL) and stirred at 25 - 30 °C for 15 hours. The reaction mass was concentrated and purified using silica gel column chromatography (gradient elution with 0-10 % MeOH in dichloromethane) to yield the product as a pale yellow solid. Yield: 320 mg (96%). ’H NMR (400 MHz, CDC13, δ ppm): 1.35 (s, 3H), 2.30 (s, 3H), 3.47 (dd, J = 16.4 Hz, 1.7 Hz 1H), 3.58 (dd, J = 16.4 Hz, 4.4 Hz 1H), 3.89 (s, 3H), 4.6 (s, 1H), 4.69 (m, 1H), 4.89 (ABquartet, J = 15.9 Hz, 2H), 7.01 (s, 1H), 7.26 (s, 1H ), 7.32-7.49 (m, 10H), 9.83(s, 1H).
Step 4: Préparation of (25^S'^jR)-3-methyl-3-(4-methyl-3-methyl-imidazoL3-iuml-ylmethyl)~4,4,7-trioxo-4-thîa-l-aza-bicyclo[3.2.0|heptane-2-carboxylate
i
To a suspension of (25,3S,5R)-3-methyl-3-(4-methyl-3-methyl-imidazol-3-iuml-ylmethyl)-4,4,7-trioxo-4-thia-l-aza-bicyclo[3.2.0]heptane-2-carboxylic acid benzhydryl ester (310 mg, 0.62 mmol) was added m-cresol (3 mL) and stirred at room température ovemight. Hexane (3 x 25mL) was added to the reaction mixture and stirred for 5 minutes then decanted. Diethyl ether (15 mL) was added to it. The solid obtained was dtluted with water and treated with Amberlite LA-2 resin (30% solution in dichloromethane), followed by dichloromethane. The aqueous layer was lyophilised to yield the product as a pale yellow solid. Yield: 130 mg (75%). *H NMR (400 MHz,
DaO) 8 ppm: 1.52 (s, 3H), 2.31 (s, 3H), 3.47 (dd, J = 16.7Hz, 1.3Hz 1H), 3.71 (dd, J = 16.7Hz, 4.1 Hz 1H), 3.80 (s, 3H), 4.39 (s, 1H), 4.92 (ABquartet, J = 15.4 Hz, 2H), 5.08 (m, 1H), 7.38 (s, 1H ), 8.86 (s, 1H). Mass m/z: 328 (M+l).
The examples below are provided by way of illustration only and should not be considered to limit the scope of the invention. Variation and changes, that are obvious to one skilled in the art, are intended to be within the scope and nature of the invention. Biology:
Détection of KPC/ESBL producing Enterobacteriaceae
In this experiment, Compound-1 is used as a diagnostic reagent for the détection of β-lactamases belonging to the families KPC & ESBL (e.g., SHV18) producing Enterobacteriaceae. A simple set of absorbent paper disks impregnated with antibiotic on agar medium is used for the détection. When the bacterial strain expresses β-lactamases, the zone of inhibition in combination with Compound-1 will be significantly larger than the antibiotic alone.
Methodology 1:
• 0.5 McFarland of the test organism was inoculated at 1:10 dilution on Muller Hinton Agar plates o Test organisme: Klebsiella pneumoniae (K.p) ATCC BAA-1705, Klebsiellapneumoniae ATCC 700603, Escherichia coli (E.c) Ecoli233 • Carbapenem (e.g., Imipenem [IPM] 10 pg) and cephalosporin (e.g., Ceftazidime [CAZ] 30 pg) paper disks (7 mm) were placed on the inoculated agar plates • Compound-1 (60 pg) disk was placed at a distance of 7 & 10 mm from the carbapenem and cephalosporin disks.
• The presence of expressed carbapenemases or ESBLs was measured as the expansion of Imipenem or Ceftazidime’s inhibition zones due to synergy in the presence of Compound-1.
Results:
Synergy was observed as an increase of the Imipenem or Ceftazidime zone adjacent to Compound-1 containing disk (Figure 1).
Methodology 2:
The methodology remains the same as Methodology 1 except the following change · Compound-1 (60 gg) was added on the same disk in combination with a carbapenem (e.g., Imipenem 10 gg) or cephalosporin (e.g., Ceftazidime 30 gg) and placed on the înoculated agar plate.
• The presence of the expressed carbapenemases or ESBLs was measured as an increase in Imipenem or Ceftazidime’s zone diameter in combination with
Compound-1 comparée! to antibiotic alone.
Results
The inhibitoiy activity of Compound-1 on carbapenemases or ESBLs was demonstrated by an increase in the zone diameter (Table 1) of Imipenem or Ceftazidime in combination with Compound-1 compared to antibiotic alone (Figure 1).
Methodology 1 in figures (A), (B) & (C) show an increase in the zone of inhibition of Imipenem or Ceftazidime adjacent to compound-1 containing disk when kept at a distance of 10 mm and 7 mm, Methodology 2 in figures (A), (B) & (C) show an increase in the zone of inhibition of Imipenem or Ceftazidime in combination with compound-1 (IT & CT) rather than the antîbîotic alone (I & C). Both the methods in 20 (D) do not show increase in the zone of inhibition and that compound-1 does not show any zone of inhibition, due to the absence of β-iactamase in the strain.
Results for isolâtes with KPC enzymes are shown in Table 1.
Table 1: Zone of inhibition (ZOI) for clinical isolâtes with class A carbapenemases and ESBL
Phenotype | Organism | Strain ID | ZOI( | mm) | ||
CAZ | 1PM | |||||
Alone | + Compound-1 | Alone | + Compound-1 | |||
KPC2 | K. pneumoniae | ATCC BAA-1705 | 12 | 18.5 | 14.5 | 20 |
KPC3 | E. coli | Ecoli233 | 11 | 22.5 | 14 | 20 |
SHV18 | K. pneumoniae | ATCC 700603 | 12 | 23 | 25 | 25 |
β-lac-ve | E. coli | ATCC 25922 | 25 | 25 | 26.5 | 26.5 |
• Compound-1 increased the zone of inhibition of Ceftazidime from 12 to 18.5 mm and 11 to 22.5 mm against the tested KPC2 and KPC3 producîng strains respectively.
• Compound-1 increased the zone of inhibition of Imipenem from 14.5 to 20 mm and 14 to 20 mm against the tested KPC2 and KPC3 producîng strains respectively.
• Compound-1 increased the zone of inhibition of Ceftazidime from 12 to 23 mm against the tested SHV18 producing strain whîle there was no change in the diameter of Imipenem with or without Compound-1 indicating the inhérent activity of Imipenem against this strain.
• Against the β-lactamase négative strain, there is no impact of Compound-1 either on Ceftazidime or Imipenem since both these antibiotics hâve inhérent activity against this strain.
Conclusion:
Compound-1 can be used as a diagnostic tool for the détection of β-lactamases including KPC.
In vitro Testing
The β-lactam compounds of formula (I) described herein were assessed in combination with β-lactam antibiotics for its potential as β-lactamase inhibitor against carbapenemase enzymes. The compounds described herein were assessed in vitro for antibacterial activity against for example KPC producing & KPC expressîng bacterial gram négative strains, β-lactamase inhibitory assay with these enzymes. The β-lactam compounds having a substitution on the heterocyclyl nitrogen atom(s) show significant β-lactamase inhibiting property. For comparative studies, Tazobactam, Clavulanic acid and Sulbactam were used along wîth the β-lactam antibiotics. Carbapenems, Cephalosporins, Monobactams and Penems (including those of veterinaiy use) were chosen as the antibacterial agents.
In vitro Antimicrobiai Testing by determining the Minimum Inhibitory concentration (MIC): Broth micro dilution method
The β-lactam compound was tested for in vitro antibacterial activitîes by the broth micro-dilution or agar dilution method as specified in documents published by Clinical and Laboratory Standards Institute (CLSI), USA (formerly NCCLS). Approved standard M7-A7, Jan 2006, CLSI, Wayne, Pennsylvania, USA and Ml 00S18, Januaiy 2008, CLSI, Wayne, Pennsylvania, USA.
Synergistic broth micro-dilution MIC was done in checkerboard format with a range of concentrations of the antibacterial agents along with several concentrations of the BLI compounds and other comparator BLI agents in 96 well microtitre plates. Briefly, stock solutions (e. g. 2560 & 1280 pg/mL) of the β-lactam antibiotics is made in water, 0.1 M Phosphate buffer, pH 6.0 or pH 7.0 or appropriate solvents accordingly. Similarly stock solutions of the BLI agents including the compound-1 were made. β-lactam antibiotics were screened in a concentration range of 0.06-128 pg/mL. BLI agents including the BLI compounds were tested in a concentration range of 1-64 pg/mL. Working solutions of ail were made by appropriate dilutions in cation adjusted Mueller Hinton broth (caMHB). Two fo!d dilutions of the antibacterial agents were done from the working solutions in caMHB serially in the wells of the 96 well microtitre plates. BLI agents including the BLI compounds were also serially diluted and then each concentration to be tested was added to each of the different antibacterial concentration. The BLI compounds, other comparator BLIs and ail the antibacterial agents were also tested individually. The bacterial inoculum was prepared by picking 3 to 5 well isolated bacterial colonies with the same morphological appearance from an 18-24 h old culture and adjusting the turbidity of the saline suspension to 0.5 McFarland turbidity standard équivalent to a bacterial population of -lxlO8 colony forming units (CFU) per mL of suspension. The suspension was diluted 1:100 in caMHB to get a bacterial population of ~1χ10ό CFU/mL as inoculum. This bacterial inoculum was added into the wells of the microtitre plate containing caMHB with antibacterîals or antibacterials + BLI agents in equal volume to the volume of the caMHB with antibacterials or antibacterials + BLI agents. Hence, the final inoculum becomes half (-5x105 CFU/mL) and the concentrations of the tested antibacterials and combinations also becomes half. The inoculated plates were incubated at 35 °C in an ambient atmosphère for 18-20 h. The plates after incubation were observed with naked eye with the aid of optical mirror and MIC was recorded as the concentration, which showed no growth or Visual turbidity of the inoculated culture.
In agar dilution method briefly, stock solutions of the cephalosporins for veterinary use (e.g. 2 mg/mL) was made in water, 0.1 M phosphate buffers or appropriate solvents and the solution was serially two fold diluted. Compound-1 was dissolved in water and Tazobactam (comparator BLI) in 0.1 M phosphate buffer, pH 6.0 to get a solution of l mg/mL. Cephalosporins were screened in a concentration range of 0.5-32 pg/mL. For combination, Tazobactam or the Compound-1 described herein were tested at a fîxed concentration of 4 pg/mL along with the cephalosporins concentration ranging from 0.5 to 32 pg/mL. Cephalosporins alone and in combination with the compound-1 or Tazobactam from each concentration was added to 20 mL of molten Mueller Hinton agar that has been cooled to 40-50 °C and poured in pétri dishes. The compound of formula (I) and Tazobactam were also tested individually. The bacterial inoculum was prepared by picking 3 to 5 well isolated bacterial colonies with the same morphologicai appearance from an 18-24 h old culture and adjusting the turbidity of the saline suspension to 0.5 McFarland turbidity standard équivalent to a 10 bacterial population of ~lxl08 CFU per mL of suspension. The suspension was diluted 1: 10 in saline to get a bacterial population of ~lxl07 CFU/mL as inoculum. This bacterial inoculum was inoculated onto the prepared pétri dishes by a multipoint inoculator with each inoculum spot containing ~lxl04 CFU of the bacterial strain. The inoculated pétri dishes were incubated at 35 °C in an ambient atmosphère for 18-20 h.
The pétri dishes after incubation were placed on a dark non-reflecting surface and the MIC was recorded as the concentration, which showed no growth of the inoculated culture.
Table 2: Minimum inhibitory concentration (MIC) of Imipenem in combination with β-lactamase inhibitor (BLI) Compound-12 against Klebsiella pneumoniae carbapenemase (KPC) producing strains
KPC type | Strains | MIC (pg/mL) of imipenem in combination with BLI at 4 or 16 pg/mL | ||||||||||
No BLI | Compound-13 | Compound-M | Compound-12 | Compound-1 | Tazobactam | |||||||
4 | 16 | 4 | 16 | 4 | 16 | 4 | 16 | 4 | 16 | |||
KPC2 | K. pneumoniae ATCC BAA1705 | 32- 64 | 2 | 2 | 8 | 8 | 4 | 4 | 4 | <0.5-1 | 16 | 8 |
KPC2 | K. pneumoniae UMM3 | 8 | NA | NA | 8 | NA | 2 | NA | 1 | NA | 4 | NA |
KPC2* | E. cloacae 01 MGH 049 | 8 | NA | NA | 8 | NA | 8 | NA | 4 | NA | 8 | NA |
KPC3 | E. colt Ecoli233 | 16 | 8 | 1 | 16 | 16 | 4 | 1 | 4 | 1 | 8 | 8 |
KPC3 | K. pneumoniae NCTC 13438 | 128 | NA | NA | 64 | NA | 64 | NA | 32 | NA | 64 | NA |
NA: Not available * Presence of AmpC was observed phenotypically
Compound-12 shows improved activity against the KPC (2 & 3) producing strains within the range similar to Compound-1, while Compound-M is only 25 moderately active not within the expected range of activity.
Table-3a: MIC of Penems or Monobactam/Compound-1 against KPC-2 producing K. pneumoniae (ATCC B AA-1705)
BLI | BLI conc. (pg/mL) | IMP | MER | ERT | FAR AZT | BLI | |
MIC (pg/mL) | |||||||
32-64 | 32-64 | >64 | >64 | >64 | >64 | ||
+ Compound-1 | 2 | 4-8 | 16 | NA | NA | NA | |
4 | 4 | 4-8 | 32 | >64 | >64 | ||
8 | 2 | 2-4 | 16 | >64 | NA | ||
16 | 1 | 1 | 8 | 64 | 64 | ||
64 | <0.5-1 | <0.5 | <0.5 | 4 | <0.5 | ||
+ Tazobactam | 2 | 16 | 32 | NA | NA | NA | >64 |
4 | 16 | 32 | >64 | >64 | >64 | ||
8 | 8-16 | 16-32 | >64 | >64 | NA | ||
16 | 8 | 8-16 | 64 | >64 | >64 | ||
64 | 4-8 | 4 | 32 | >64 | >64 | ||
+ Clavulanic acid | 2 | 8-16 | 16 | 32 | >64 | NA | >64 |
4 | 8-16 | 4-8 | 64 | >64 | >64 | ||
8 | 4-8 | 4 | NA | NA | NA | ||
16 | 2 | 4 | 32 | >64 | >64 | ||
64 | <0.5 | 2 | 8 | >64 | 64 | ||
+ Sulbactam | 2 | 16-32 | 32 | NA | NA | NA | >64 |
4 | 16-32 | 32 | >64 | >64 | >64 | ||
8 | 16 | 32 | >64 | >64 | NA | ||
16 | 8 | 32 | >64 | >64 | >64 | ||
64 | 8 | 16 | 64 | >64 | >64 |
IMP: Imipenem, MER: Meropenem, ERT: Ertapenem, FAR: Faropenem & ΑΖΎ: Aztreonam.
Compound-1 synergized with Imipenem and Meropenem better than 10 Tazobactam or Clavulanic acid or Sulbactam against KPC-2 producing strain ATCC BAA1705 at >4 pg/mL concentration. It also showed better synergy with Ertapenem, Faropenem and Aztreonam than the above comparators at 64 pg/mL concentration (Table-3a). Similarly, the following compounds in the sériés showed the restoratîon of antibacterial activity of Imipenem & Meropenem (Table- 3b).
Table 3b: Penems BLI compounds against KPC-2 producing JC. pneumoniae (ATCC BAA-1705)
BLI | BLI conc. (pg/mL) | MIC (pg/mL) | ||
Imipenem | Meropenem | BLI | ||
32-64 | 32-64 | |||
Compound-4 | 4 | 4 | 8 | >16 |
16 | 1 | 4 | ||
Compound-2 | 4 | 4 | 8 | >16 |
16 | 1 | 2 | ||
Compound-6 | 4 | 8 | 16 | >16 |
16 | 8 | 4 | ||
Compound-5 | 4 | 8 | 8 | >16 |
16 | 1 | 2 | ||
Compound-8 | 4 | 8 | 8 | >16 |
16 | 4 | 4 | ||
Compound-1 | 4 | 4 | 8 | >16 |
16 | 1 | 1 | ||
Tazobactam | 4 | 16 | 32 | >16 |
16 | 8 | 8-16 |
Table-4: Human cephalosporins/compound-1 against KPC-2 producing K. pneumoniae (ATCC BAA-1705)
BL1 | BLI conc. (pg/mL) | CEF CTX | CTZ CTB BLI | |||
MK | C (pg/mL) | |||||
>128 | >128 | >128 | >64 | >64 | ||
+ Compound-1 | 2 | 64 | 32 | >64 | >64 | |
4 | 32 | 16 | >64 | >64 | ||
8 | 16 | 16 | 64 | >64 | ||
16 | 4 | 4 | 4 | 64 | ||
64 | <0.5 | <0.5 | 1 | <0.5 | ||
+ Tazobactam | 2 | 64 | >64 | >64 | >64 | >64 |
4 | 64 | 32-64 | >64 | >64 | ||
8 | 32 | 32 | >64 | >64 | ||
16 | 32 | 32 | >64 | >64 | ||
64 | 32 | 32 | 64 | >64 | ||
+ Clavulanic acid | 2 | 64 | 32-64 | >64 | >64 | >64 |
4 | 64 | 32-64 | >64 | >64 | ||
8 | 32 | 16-32 | >64 | >64 | ||
16 | 32 | 16 | 64 | >64 | ||
64 | 8 | 8 | 16 | 64 | ||
+ Sulbactam | 2 | >64 | >64 | >64 | >64 | >64 |
4 | >64 | >64 | >64 | >64 | ||
8 | 64 | 64 | >64 | >64 | ||
16 | 64 | 32 | >64 | >64 | ||
64 | 64 | 32 | 64 | >64 |
CEF: Cefepime, CTX: Cefotaxime, CTZ: Ceftazidime & CTB: Ceftobiproie
Compound-1 synergized with Cefepime better than Tazobactam or Clavulanic 10 acid or Sulbactam against KPC-2 producing strain ATCC BAA1705 at >16 pg/mL concentration. It also showed better synergy with Cefotaxime & Ceftazidime than the above comparators at 64 pg/mL concentration. Ceftobiproie did not show any synergy at the tested conc. against ail the compared compounds (Table-4).
Table-5: Veterinary cephalosporins/compound-l against KPC-2 producing K. pneumortiae (ATCC BAA-1705)
BLI | BLI conc. (pg/mL) | CFQ CFF CFD CFL BLI | ||||
MIC (pg/mL) | ||||||
>64 | >64 | >64 | >64 | >64 | ||
+ Compound-1 | 1 | >64 | >64 | NA | NA | |
2 | >64 | >64 | NA | NA | ||
4 | 64 | >64 | >64 | >64 | ||
8 | 64 | 64 | NA | NA | ||
16 | 8-16 | 16-32 | >64 | 32 | ||
32 | 2-4 | 4 | NA | NA | ||
64 | 1 | 2-4 | 64 | 8 | ||
+ Tazobactam | 1 | >64 | >64 | NA | NA | >64 |
2 | >64 | >64 | NA | NA | ||
4 | >64 | >64 | >64 | >64 | ||
8 | 64 | >64 | NA | NA | ||
16 | 64 | >64 | >64 | >64 | ||
32 | 64 | 64 | NA | NA | ||
64 | 64 | 64 | >64 | >64 |
CFQ: Cefquinome, CFF: Ceftiofur, CFD: Cefadroxil & CFL: Cefalonium
Compound-1 synergized with cephalosporins for veterinary use Cefquinome and Ceftiofur better than Tazobactam against KPC-2 producing strain ATCC 10 BAA1705 at >32 pg/mL concentration. Cefadroxil & Cefalonium did not show the desired synergy at the tested concentrations (Table-5).
Table-6a: Carbapenems & human cephalosporins/compound-l against KPC-3 expressing E. coli (J53 R6206)
BLI | BLI conc. (pg/mL) | 1MP MER CEF CTX CTZ CTB BLI | ||||||
MIC (pg/mL) | ||||||||
2-4 | 2-4 | >16 | >32 | >32 | >32 | >8 | ||
+ Compound- 1 | 2 | 1 | <0.06 | 1 | 1 | 2 | 2 | |
4 | 0.5 | <0.06 | 0.25 | <0.25 | 1 | 0.5 | ||
8 | 0.5 | <0.06 | <0.125 | <0.25 | 1 | <0.25 | ||
+ Tazobactam | 2 | 2 | 1 | 16 | 8 | 32 | 32 | >8 |
4 | 2 | 0.5 | 8 | 8 | 32 | 16 | ||
8 | 1 | 0.5 | 4 | 4 | 32 | 16 | ||
+ Clavulanîc acid | 2 | 1 | 1 | 8 | 4 | 32 | 8 | >8 |
4 | 1 | 1 | 8 | 1 | 32 | 8 | ||
8 | 0.5 | 0.5 | 1 | <0.25 | 8 | 2 | ||
+ Sulbactam | 2 | 4 | 2 | 16 | >32 | 32 | 32 | >8 |
4 | 2 | 1 | 16 | 16 | 32 | 32 | ||
8 | 2 | 1 | 8 | 8 | 32 | 16 |
IMP: Imipenem, MER: Meropenem, CEF: Cefepime, CTX: Cefotaxime, CTZ: Ceftazidime & CTB: Ceftobiprole
Compound-1 synergized with Imipenem, Meropenem, Cefepime, Cefotaxime, Ceftazidime and Ceftobiprole better than Tazobactam or Clavulanic acid or Sulbactam against KPC-3 expressing E. coli strain J53 R6206 at >2 μg/mL concentration (Table6a). Sîmilarly, the following compounds in the sériés showed the restoration of antibacterial activity of Imipenem & Meropenem (Table- 6b)
Table-6b: Carbapenems BLI compounds against KPC-3 expressing E. coli (J53 R6206)
BLI | BLI conc. (pg/mL) | M | IC (pg/mL) | |
Imipenem | Meropenem | BLI | ||
2-4 | 2-4 | |||
Compound-4 | 4 | 0.5 | <0.125 | >16 |
16 | 0.25 | <0.125 | ||
Compound-2 | 4 | 0.5 | <0.125 | >16 |
16 | 0.25 | <0.125 | ||
Compound-6 | 4 | 1 | 0.5 | >16 |
16 | 0.5 | <0.125 | ||
Compound-5 | 4 | 0.5 | <0.125 | >16 |
16 | 0.25 | <0.125 | ||
Compound-8 | 4 | 1 | 0.25 | >16 |
16 | 0.25 | <0.125 | ||
Compound-1 | 4 | 0.5 | <0.125 | >16 |
16 | 0.25 | <0.125 | ||
Tazobactam | 4 | 2 | 0.5 | >16 |
16 | 1 | <0.125 |
Table-7: Veterinary cephalosporins/Compound-1 against KPC-3 expressing E coli (J53 R6206)
BLI conc. | CFQ | CFF | CFD | CFL | BLI | |
BLI | MIC (pg/mL) | |||||
(pg/mL) | 16 | 16 | >32 | 32 | >16 | |
+ Compound-1 | 4 | <0.5 | <0.5 | >32 | 4 | |
+ Tazobactam | 4 | 8 | 2 | >32 | 32 | >16 |
CFQ: Cefquinome, CFF: Ceftiofur, CFD: Cefadroxil & CFL: Cefalonium
Compound-1 synergized with Cephalosporins for veterinary use Cefquinome Ceftiofur & Cefalonium better than Tazobactam against KPC-3 expressing E. coli strain J53 R6206 at 4 pg/mL concentration. Cefadroxil did not show the desired synergy at the tested concentrations (Table-7).
β-Lactamase inhibitory assay with carbapenemases
The Compound-1 was subjected to β-lactamase inhibitory assay to déterminé IC50 and to compare that with the comparator BLI agents as described elsewhere (Bebrone et. al., Antimicrob. Agents. Chemother, 2001, 45(6): 1868-1871; Jamieson et. al, Antimicrob. Agents. Chemother, 2003, 47(5): 1652-1657). Briefly, enzyme extracts 10 from KPC-2 producing and K.PC-3 expressing bacterial gram négative strains were used to study the β-lactamase inhibitory activity and détermination of ICjo using CENTA as the substrate for β-lactamase.
Table-8: β-lactamase enzyme inhibitory assay of Compound-1 with carbapenemases
BLI | 1C5O (pM) | |
KPC2 | KPC2 | |
Compound-l | 190 | 10.7 |
Tazobactam | 980 | 71 |
Clavulanic acid | 330 | 92 |
Sulbactam | 1400 | 235 |
The IC50 of compound-1 is lower than the compared BLIs against the crude
KPC-2 & 3 enzyme extracts indicating its superior binding hence potency of the BLI of compound-1 of formula (I) (Table-8).
TabIe-9: Comparison of MIC (pg/mL) of Piperacillin in combination with standard Tazo and Novel Inhibitor compounds against spécifie Extended spectrum β-lactamase (ESBLs) producing Gram-negative isolâtes from ATCC
ATCC strains | MIC of Piperacillin with different concentrations of Tazo or Compound-I2 | |||||||||
Inhibitor Conc.: | 2 pg/mL | 4 | pg/mL | |||||||
ESBL Phenotype! | Tazo | Compound-M | Compound-12 | Tazo | Compound-M | Compound-12 | Tazo | Compound-M | Compound-12 | |
E.coli BAA-201 | TEM-3 | 4 | 4 | 2 | 4 | 4 | 4 | 2 | 4 | 4 |
E.coli BAA-197 | TEM-12 | 64 | 4 | 4 | 8 | 8 | 4 | 4 | 4 | 4 |
E.coli BAA-198 | TEM-26 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
P.mirabilis BAA-663 | TEM-89 | 8 | 64 | 8 | 8 | >128 | 16 | 4 | >128 | >128 |
E.coli BAA-199 | SHV-3 | >128 | >128 | >128 | >128 | >128 | >128 | >128 | >128 | 2 |
E.coli BAA-200 | SHV-4 | >128 | >128 | 32 | >128 | >128 | 8 | 4 | >128 | 4 |
Kpneumoniae 700603 | SHV-18 | 16 | 16 | 8 | 16 | 32 | 16 | 16 | 16 | 8 |
Itt vivo eflicacy of Compound-1 against KPC carbapenemase producîng strains
The Compound-1 is a potent inhibitor of ESBLs and its inhibitory activity against KPC enzymes was demonstrated in vitro. Compound-1 was evaluated against KPC2 producîng K. pneumoniae ATCC BAA 1705 in the pharmacodynamies models of mice systemic infection and thigh infection for in vivo translation of its inhibitory activity against KPC2. In these models, eflicacy of β-lactams as single agents deteriorated due to KPC2 mediated hydroiysis. By combining compound-1 with βlactams, its potential to restore or enhance the eflicacy of β-Iactams was assessed.
Method:
Mice systemic infection model
Female Swiss Albino mice, weighing 18 - 22 g were used for ali studies. For each dose group, 5 or 6 mice were included. Study protocole were reviewed and approved by Institutional Animal Ethical Committee, Orchid Research Laboratories Limited. Mice were housed in individually ventilated cages provided with food and water ad libitum, throughout the study period. From ovemight culture in Brain-Heart Infusion agar medium, challenge inoculum with required bacterial density was prepared in normal saline containing Hog gastric mucin. In studies involved with doripenem, washed bacterial cells was used. Each mouse was infected with of challenge inoculum by intra-peritoneal injection.
Piperacillin with β-lactamase inhibitor (BLI) combinations; Increasing concentrations of piperacillin and BLIs (Compound-1 or tazobactam) as single agents or piperacillin in combination with BLIs at 1:1 ratio were prepared in aqueous agar (Bacto agar). Infected mice were dosed sub-cutaneously, with drug préparations at three different time points post-infection.
Imipenem with BLI combinations: Increasing concentrations of Imipenem as single agent or in combination with fixed concentration of BLIs were used to dose infected mice, sub-cutaneously. In this experiment Imipenem was always administered along with cilastatin.
Doripenem with BLI combinations: Increasing concentrations of doripenem as single agent or in combination with fixed concentration of BLIs were used to dose infected mice, sub-cutaneously.
Survival of the treated mice were monitored twice a day, up to 7 days postinfection. Efficacy dose 50 (ED50) was calculated by Reed and Muench method (Reed, L.J.; Muench, H.. A simple method of estimating fifty percent endpoints. The American Journal ofHygiene, 1938,27:493-497.).
Neutropénie mice thlgh infection model (Human adapted model)
Female Swiss Albino mice weighing 24 - 30 g were used for ail studies. Study protocols were reviewed and approved by Institutional Animal Ethical Committee, Orchid Research Laboratories Limited. Mice were rendered neutropénie by intraperitoneal cyclophosphamide injections. Log phase culture in brain heart infusion broth was injected in to mice thighs. Imipenem or Doripenen alone or in combination were administered sub-cutaneously in decreasing fractionated doses every 15 minutes over the period of 5.5 h (Flückiger, U. et al.. “Intégration of pharmacokinetics and pharmacodynamies of Imipenem in a human-adapted mouse model*. Antimicrobial Agents and Chemother, 1991,35(9): 1905-1910). The Compound-1 or tazobactam was administered sub-cutaneously as bolus dose at the start of dosing. Efficacy end point was 6 h in Imipenem studies and 8 h in Doripenen studies.
Efficacy of piperacillin restored by Compound-1 against KPC2 K. pneumoniae ATCC BAA 1705 in mice System ic infection model
Piperacillin alone was not efficacious up to 800 mg/kg. The Compound-1 restored the efficacy of piperacillin as piperacillin demonstrated an ED50 of 50 mg/kg in combination with Compound-1 at 1:1 ratio. As Compound-1 atone was not efficacious, piperacillin efficacy in combination was attributed to KPC2 enzyme inhibitory activity of Compound-1. The clinically used tazobactam however could not restore the piperacillin efficacy as its combination with piperacillin at 1:1 ratio up to >200 : >200 mg/kg did not show efficacy (Table 10).
Table 10: Comparison of efficacy of piperacillin in combination with Compound1 versus tazobactam
Dose group | EDso (mg/kg) |
Piperacillin | >800 |
Compound-1 | >64 |
Tazobactam | >200 |
Piperacillin: Compound-1 at 1:1 ratio | 50:50 |
Piperacillin:Tazobactam at 1:1 ratio | >200 : >200 |
Efficacy of Imipenem enhanced by Compound-1 against KPC2 A' pneumoniae ATCC BAA 1705 in mice systemic infection model
Imipenem alone showed an EDso of 8.9 mg/kg. Combining compound-1 at fixed 64 mg/kg resulted in enhancement of efficacy with ED50 of 2.2 mg/kg. Addition of tazobactam at same dose with Imipenem resulted in ED50 of 4 mg/kg. Significant increase in efficacy of Imipenem by compound-1 was due to its inhibitory activity on KPC2 enzyme (Table 11).
Table 11: Comparison of efficacy of Imipenem in combination with Compound-1 versus tazobactam
Dose group | ED.» (mg/kg) |
Imipenem | 8.9 |
Imipenem + Compound-1 (64 mg/kg) | 2.2 |
Imipenem + Tazobactam (64 mg/kg) | 4 |
Efficacy of Doripenen enhanced by Compound-1 against KPC2 K. pneumoniae ATCC BAA 1705 in mice systemic infection model
Doripenem alone and Doripenen in combination with compound-1 or tazobactam were evaluated. The compound-1 or tazobactam were tested at 20 mg/kg and 64 mg/kg. Doripenem alone showed an ED50 of 14.14 mg/kg. Its efficacy was significantly enhanced by compound-1 at 20 mg/kg with an ED50 of 1.4 mg/kg and at 64 mg/kg with an ED50 of 1.62 mg/kg. Tazobactam improved the efficacy of Doripenen marginally with an ED50 of 11.89 mg/kg and 6.48 mg/kg at tazobactam doses of 20 and 64 mg/kg respectively (Table 12)
These results suggest the potent inhibitory activity of compound-1 on KPC2 resulting in protection of Doripenen form KPC2 mediated hydrolysis thus restoring the efficacy of Doripenen.
Table 12: Comparison of efficacy of Doripenen in combination with Compound-1 versus tazobactam
Dose group | EDm (mg/kg) |
Doripenem | 14.14 |
Doripenem + Compound-l (20 mg/kg) | 1.4 |
Doripenem + Compound-1 (64 mg/kg) | 1.62 |
Doripenem + Tazobactam (20 mg/kg) | 11.89 |
Doripenem + Tazobactam (64 mg/kg) | 6.48 |
Eflîcacy of Imipenem enhanced by Compound-1 against KPC2 K. pneumoniae ATCC BAA 1705 in neutropénie mice thigh infection model
The mean initial bacterial load at the start of therapy was 1.8E+06 CFU/thigh. Imipenem 140 mg/kg administered as fractionated doses over the period of 5.5 h was not efficacious; bacteria grew to 6.8E+06 CFU/thigh after 6 h of therapy. Combining Imipenem with compound-1 at 140 mg/kg as bolus dose restored the efïïcacy as bacterial load reduced to 2.1E+05 CFU/thigh (Table 13). This experimental resuit showed that compound-1 demonstrated inhibitory potential in the tough mice thigh infection model.
Table 13: In vivo pharmacodynamies (Thigh infection model) of Imipenem in combination with Compound-1
Dose group | Bacterial load (CFU/thigh) |
Initial bacterial load | 1.81E+06 |
Infection control | 4.6E+07 |
Imipenem 140 mg/kg treated | 6.8E+06 |
Imipenem (140 mg/kg ) + Compound-1 (140 mg/kg) | 2.1E+05 |
Efïicacy of Doripenem enhanced by compound-1 against KPC2 K. pneumoniae ATCC BAA 1705 in neutropénie mice thigb infection model
Three experiments were carried out where Doripenen alone or in combination with compound-1 or tazobactam (two experiments) were evaluated. Doripenem 70 mg/kg was administered in fractionated doses over the period of 5.5 h (Flückiger, U. et al. “Intégration of pharmacokinetics and pharmacodynamies of Imipenem in a humanadapted mouse model*. Antimicrobial Agents and Chemother,. 1991, 35(9): 19051910). Compound-1 or tazobactam was administered as bolus dose at initiation of therapy. Efïicacy end point was 8 h after initiation of therapy.
The initial bacterial load ranged from 1.4E+07 - 3.1E+O7 CFU/thigh. Doripenem 70 mg/kg alone exerted a static effect on the bacterial load. Mice treated with Doripenen alone showed bacterial load of 5.4E+06 - 2.6E+07 CFU/thigh. Combining compound-1 at 35 mg/kg with Doripenen brought the bacterial load down ίο 7.9E+05 - 1.3E-H16 CFU/thigh. Doripenem was also combined with tazobactam at 35 mg/kg in two experiments. Tazobactam dîd not hâve impact on efïicacy of Doripenen as mice showed bacterial load of 1.2 E+07-1.6E+07 CFU/thigh (Table 14).
Table 14: In vivo pharmacodynamies (Thigh infection mode!) of Doripenem in combination with Compound-1
Dose group | Bacterial load (range) (CFU/thigh) |
Initial bacterial load | 1.4E+07-3.1 E+07 |
Infection control | 7.3 E+07- 1.6 E+08 |
Doripenem 70 mg/kg treated | 5.4 E+06-2.6 E+07 |
Doripenem (70 mg/kg) + Compound-1 (35 mg/kg) | 7.9 E+05 - 1.4 E+06 |
Doripenem (70 mg/kg) + Tazobactam (35 mg/kg) | 1.19 x 10'-1.6 x 10' |
Conclusion
In ali these experiments, efficacy of β-lactams as single agents deteriorated as they were not stable to KPC2. Being an inhibitor of KPC2, compound-1 restored or io significantly enhanced the efficacy of β-lactams.
Claims (24)
1. A compound of formula (I), their dérivatives, analogs, tautomeric forms, stereoisomers, polymorphe, solvatés, métabolites, prodrugs, hydrates, pharmaceutically acceptable salts and esters, for use in the inhibition of βlactamases produced by bacteria; restoring/potentiating the activity of antibiotics, 10 comprising administering a therapeutically effective amount of compound of formula (I), to a subject in need thereof;
wherein
A = CorN;
Het represents optionally substituted three- to seven-membered heterocyclic ring;
15 R1 represents carboxylate anion or -COOR4 wherein R4 represents hydrogen, CiCealkyl, Co-Cioaryl, Cô-CtoarylCi-Cfialkyl, methoxybenzyl, nitrobenzyl, silyl, diphenylmethyl, proxetil, axetil, cilexetil, pivoxil, hexetil, daloxate or a pharmaceutically acceptable sait;
R2 and R3 independently represent hydrogen, halogen, amino, protected amino or 20 optionally substituted Ci-Cealkyl, C2-Cealkenyl and C2-C6alkynyl;
R represents substituted or unsubstituted Ci-Côaikyl, C2-Céalkenyl, C6-C|oaryl, C6CioarylCi-Cealkyl, C3-Ci2cycloalkyl, oxo, heterocyclyl and heterocyclylalkyl groups;
when the groups R, R2 and R3 are substituted, the substituents which may be one or 25 more are selected from lower alkyl (Ci-C4alkyl selected from the group consisting of methyl, ethyl, propyl and isopropyl); lower alkoxy (Ci-C4alkoxy selected from the group consisting of methoxy, ethoxy and propoxy); lower alkylthio (C|C4alkylthio selected from the group consisting of methylthio and ethylthio); lower alkylamino (C|-C4alkylamino selected from the group consisting of methylamino, 30 ethylamino and propylamino); cyclo(lower)alkyl (Cs-Cftcycloalkyl selected from the group consisting of cyclopentyl and cyclohexyl); cyclo(lower)alkenyl (CsCecycloalkenyl selected from the group consisting of cyclohexenyl and cyclohexadienyl); hydroxy; halogen (chloro, bromo, fluoro and iodo); amino;
5 protected amino; cyano; nitro; carbamoyl; -CONHCi-C4alkyl-COO-Ci-C4alkyl; carboxy; protected carboxy; -COO-Ci-C4alkyl; -CO-heterocyclyl; sulfonyl; sulfamoyl; imino; oxo; amino(lower)alkyl selected from the group consisting of aminomethyl, aminoethyl and aminopropyl; halo(lower)alkyl selected from the group consisting of trifluoromethyl (-CF3), fluoromethyl, fluoroethyl, bromomethyl 10 and difluoromethyl; carboxylic acid and carboxylic acid dérivatives selected from the group consisting of hydroxamic acid, ester and amide.
2. The compound for use as claimed in claim 1, wherein the compounds are selected from formula (II),
R1
15 their dérivatives, analogs, tautomeric forms, stereoisomers, polymorphs, solvatés, métabolites, prodrugs, hydrates, pharmaceutically acceptable salts and esters, for use in the inhibition of carbapenemases produced by bacteria; restoring/potentiating the activity of antibiotics, comprising administering a therapeutically effective amount of compound of formula (I), to a subject in need 20 thereof;
wherein:
L = CorN;
R1 represents carboxylate anion or -COOR4 wherein R4 represents hydrogen, CjCealkyl, Ce-Cioaryl, Ce-CioarylCi-Côalkyl, methoxybenzyl, nitrobenzyl, silyl,
25 diphenylmethyl, proxetil, axetil, cilexetil, pivoxil, hexetil, daloxate or a pharmaceutically acceptable sait;
R2 and R3 may be same or different and independently represent hydrogen, halogen, amino, protected amino, optionally substituted Ct-Cealkyi, Cî-Côalkenyl and Cî-Cealkynyl;
30 R represents substituted or unsubstituted Ci-Cftalkyl, C2-C6alkenyl, Cô-Cioaryl, C#· Cioaryl Cj-Céalkyl, C3-Ct2cycloalkyl, oxo, heterocyclyl and heterocyclylalkyl;
R5 is hydrogen, C|-C«alkyl, Ci-C^aikoxy, C|-C6alkylthio, Ci-Côalkylamîno, hydroxyl, halogen and trihalomethyl; and m is 0, 1 or 2.
3. The compound for use as claimed in claim 1 or 2, wherein the compound is selected from:
1 - {[(25,35,55)-2-Carboxy-3 -methy 1-4,4,7-trioxo-4-th ia-1 azabicyclo[3.2.0]hept-3-yl]methyl}-3-methyl-177-l,2,3-triazol-3-ium;
1 - {[(25,35,5A)-2-Carboxy-3-methy l-4,4,7-trioxo-4-th ia-1 azabicyclo[3.2.0]hept-3-yl]methyl} -3-ethyl-7/7-1,2,3-triazol-3-ium;
1 - {[(25,35,55)-2-Carboxy-3-methyl-4,4,7-trioxo-4-thia-1 azabicyclo[3,2.0]hept-3-y l]methyl }-3 -n-propy l-l H-1,2,3 -triazol-3 -ium ;
1 - {[(25,35,55)-2-Carboxy-3-methyl-4,4,7-trioxo-4-thîa-1 azabicyclo [3.2.0]hept-3-y 1] methyl }-3 -al ly l-l H-1,2,3-triazol-3 -ium ;
1 - {[(25,35,55)-2-Carboxy-3-methyl-4,4,7-trioxo-4-thia-1 azabicyclo[3.2.0]hept-3-yl]methyl}-3-(2-amino-2-oxoethyl)-777-l,2,3triazol-3-ium and the corresponding acid;
1 - {[(25,35,55)-2-Carboxy-3-methyl-4,4,7-trioxo-4-thia-1 azabicyclo[3.2,0]hept-3-yl] methyl} -3-(2-Abutoxy-2-oxoethy Ï)-1H-1,2,3triazol-3-ium and the corresponding acid;
1 - {[(25,35,55)-2-Carboxy-3-methyl-4,4,7-trioxo-4-thia-1 azabicyclo[3.2.0]hept-3-yl]methyl}-3-(2-morpholin-4-yl-2-oxoethyl)-7Hl,2,3-triazol-3-ium and the corresponding acid;
1 -{[(25,35,57?)-2-Carboxy-3-methyM,4,7-trioxo-4-thia-1 azabicyclo[3.2.0]hept-3-yl]methyl}-3-{2[(2-ethoxy-2-oxoethyl)amino]-2oxoethyl}-7#-l,2,3-triazol-3-ium and the corresponding acid;
1 - {[(25,35,57î)-2-Carboxy-3 -methyl -4,4,7-trioxo-4-thia-1 azabicyclo[3.2.0]hept-3-yl]methyl}-3-{2-[(3-ethoxy-3-oxopropyl)amino]-2oxoethyl}-7iAl,2,3-triazol-3-ium and the corresponding acid;
1 - {[(25,35,5Æ)-2-Carboxy-3 -methy 1-4,4,7-trioxo-4-thia-1 azabicyclo[3.2.0] hept-3 -yl] methyl} -3-(2- {[ 1 -(ethoxycarbonyi)-2hydroxypropy(]amino}-2-oxoethyl)-7/f-l,2,3-triazol-3-ium and the corresponding acid;
1 - {[(25,35,55)-2-Carboxy-3 -methy 1-4,4,7-trioxo-4-th ia-1 azabicyclo[3.2.0]hept-3-yl]methyl}-3-benzyl-17f-l ,2,3-triazol-3-ium and the corresponding acid;
(25,35,57?)-3-Methyl-3-(3-methyl-imidazol-3-ium-l-ylmethyl)-4,4,7-trioxo4-thia-l-azabicyclo[3.2.0]heptane-2-carboxylate and the correspondîng acid; and (25,35,5/?)-3-Methyl-3-(4-methyl-3-methyl-imidazol-3-ium-1 -ylmethyl)4,4,7-trioxo-4-thia-l-aza-bicyclo[3.2.0]heptane-2-carboxylate and the correspondîng acid, their dérivatives, analogs, tautomeric forms, stereoisomers, polymorphs, solvatés, métabolites, prodrugs, hydrates, pharmaceutically acceptable salts and esters.
4. The compound for use as claimed in claim l or 2, wherein the compound is,
1 - {[(2S, 3S, 5Æ)-2-Carboxy-3-methyl-4,4,7-trioxo-4-thia-1 -azabicyclo[3.2.0]hept-3yl]methyl}-3-methyl-lH-l,2,3-triazol-3-ium and its dérivatives, analogs, tautomeric forms, stereoisomers, polymorphs, solvatés, métabolites, prodrugs, hydrates, pharmaceutically acceptable salts and esters.
5. The compound of formula (I) for treating and/or preventing infections caused by bacteria producing β-lactamases comprising carbapenemases, cephalosporinases, penicilünases, ESBLs, inhibitor-resistant β-lactamases, in combination with suitable antibiotic, comprising administering therapeutically effective amount of compound of formula (I), to a subject in need thereof.
6. The compound for use as claimed in any one of the claims 1-4, for treating and/or preventing infection caused by carbapenemase producing bacteria comprising administering therapeutically effective amount of compound of formula (I), in combination with suitable antibiotics to a subject in need thereof.
7. The compound for use as claimed in any one of the claims 1-4, wherein bacteria are selected from Gram-negative bacteria.
8. The compound for use as claimed in any one of the claims 1-4, wherein the carbapenemases are selected from KPC.
9. A pharmaceutical composition comprising a compound of formula (I) as claimed in any one of the claims 1-4, as an active ingrédient for inhibiting β-lactamases.
10. A pharmaceutical composition comprising a compound of formula (I) as claimed in any one of the claims 1-4, as an active ingrédient along with
a. one or more compounds of claim 1 ;
b. one or more antibiotics and
c. one or more pharmaceutically acceptable carrier.
11. The compound for use as claimed in any one of the claims 1-4, wherein the antibiotics are β-lactam antibiotics.
12. The compound for use as claimed in claim 11, wherein the antibiotics are selected from Penicillins, Cephalosporins, Carbacephem, Oxacephem, Carbapenems, Cephamycins, Penems, Monobactams or a combination thereof.
13. The compound for use as claimed in claim 12, wherein the penicillins are selected from Amdinocillin (Mecillinam), Amoxicillin, Ampicillin, Amylpenicillin, Apalcillin, Aspoxicillin, Azidocîllin, Azlocillin, Bacampicillin, Carbenicillin, Carindacillin, Clometocillin, Cloxacillin, Cyclacillin (Ciclacillin), Dicloxacillin, Epicillin. Fenbenicillin, Floxacillin (flucloxacillin), Hetacillin, Lenampiciilin, Metampicillin, Methicillin, Mezlocillin, Nafcillin, Oxacillin, Penamecillin, Penethecillin. Penicillin G (Procaine Pencillin), Penicillin N, Penicillin O, Penicillin V (Phenoxymethyl Penicillin), Phenethicillin, Piperacillin, Pivampicillin, Propicillin, Quinacillin, Sulbenicillin, Talampicillin, Temocillin, Ticarcillin, Pivmecillinam, Benzathine Penicillin, Benzyl Penicillin, Co-amoxiclav and Lenampiciilin.
14. The compound for use as claimed in claim 12, wherein the cephalosporins are selected from Cephaloridin, Cephradine, Cefoxitin, Cephacetril, Cefinenoxime, Cephaloglycin, Cefonicid, Cefodizime, Cefpirome, Cefpiramide, Cefozopran, Cefoselis, Cefluprenam, Cefpimizole, Cefclidin, Cefpodoxime axetil, Cefteram pivoxil, Cefcapene pivoxil, Ceftobiprole, Ceftaroline, Cefoperazone, Cefquinome,
Ceftiofur, Cefovecin, Cefadroxil, Cefalonium, Cefepime, Cefotaxime, Ceftazidime, Cefetamet pivoxil, Cefditoren pivoxil, Cephaloridine, Ceftazidime, Ceftriaxone, Cefbuperazone, Cephaiothin, Cephazolin, Cephapirin, Ceftezole, Cefamandole, Cefotiam, Cefotiam hexetil, Cefuroxime, Ceftizoxime, Cefmenoxime, Cefuzonam, Cefsulodin, Cefmetazole, Cefmînox, Cephalexin, Cefradine, Cefaclor, Cefadroxil, Cefalonium, Cefprozil, Cefiiroxime axetil, Cefixime, Cefpodoxime proxetil, Ceftibuten, CXA-10l(FR264205), and Cefdinir.
15. The compound for use as claimed in claim 12, wherein the carbapenems are selected from Meropenem, Ertapenem, Doripenem, Biapenem, Panipenem, Ritipenem, Tebipenem, Tomopenem, Sulopenem, Razupenem, Imipenem, ME1036 and SM216601.
16. The compound for use as claimed in daim 12, wherein the Monobactams are selected from Aztreonam, Carumonam, Tigemonam, BAL19764 and BAL30072.
17. The compound for use as claimed in anyone of claims 1 to 4, wherein the antibiotics are selected from Imipenem, Faropenem, Doripenem, Meropenem, Ertapenem, Aztreonam, Cefepime, Cefotaxime, Ceftazidime, Ceftobiprole, Cefquinome, Ceftiofur, Cefadroxil and Cefalonium.
18. The compound of formula (I) for use as a diagnostic reagent for the détection of βlactamases including carbapenemases.
19. The compound for use as claimed in claim 18 as a diagnostic reagent for the détection of β-lactamases belonging to the familles of KPC and ESBL producing Enterobacteriaceae.
20. (2S')3S’,57î)-3-Methyl-3“(3-methyl-imidazol-3-ium“l-ylmethyI)-4,4,7-trioxo-4-Üiial-azabicyclo[3.2.0]heptane-2-carboxylate; and (2S,3S',57î)-3-Methyl-3-(4-methyl-
3-methyl-imidazol-3-ium-l -ylmethyl)-4,4,7-trioxo-4-thia-1 -azabicyclo[3.2.0]heptane-2-carboxylate, their dérivatives, analogs, tautomeric forms, stereoisomers, polymorphs, solvatés, métabolites, prodrugs, hydrates, pharmaceutically acceptable salts and esters.
21. The compound for use as claimed in claim 1 or 2, wherein the ‘subject’ is selected from patients with bacterial infections, preoperative patients, postoperative patients, patients in ICU, patients with nosocomial infections, community acquired infections and veterinaries.
22. The compound for use as claimed in anyone of daims 1,5-13 and 15 substantially as hereinbefore described with reference to the examples and/or the figures of the accompanying drawings.
23. The Compound for use as claimed in any one of daims 2-4, substantially as herein described or exemplifîed.
24. The pharmaceutical composition as claimed in daim 10, wherein the antibiotics are selected from the group consisting of Penicillins, Cephalosporins, Penems, Carbacephem, Carbapenems, Oxacephem, Monobactams, Aminoglycosides, Bacteriocins, Quinolones, Sulfonamides, Macrolides, Tetracyclines, Glycylcyclines, Oxazolidinones, Lipopeptides, Polypeptides, Rifamycins, Chloramphenicol, Polyene antifungals and dérivatives thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3555/CHE/2010 | 2010-11-25 | ||
IN3096/CHE/2011 | 2011-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
OA16437A true OA16437A (en) | 2015-10-15 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10201532B2 (en) | Compounds and their use | |
US9090616B2 (en) | Nitrogen containing compounds and their use | |
ES2427122T3 (en) | 2-substituted methyl penam derivatives | |
JP2011518871A (en) | Azabicyclo compounds, their preparation and use as pharmaceuticals, in particular as β-lactamase inhibitors | |
OA16437A (en) | Compounds and their use. | |
EP3795149A1 (en) | Inhibitor & x3b2;-lactamase | |
JP6017423B2 (en) | NDM inhibitor | |
KR20160003344A (en) | Nitrogen containing compounds and their use |